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ABSTRACT 
Cancer is one of the most common causes of death for both children and adults in 
developed countries. Neuroblastoma is a cancer of the sympathetic nervous system 
that affects infants and young children. Neuroblastoma tumors are the most 
common solid extracranial tumors in children and are also the most deadly. About 
half of the patients diagnosed are classified as high-risk, and despite an intensive 
multimodal treatment, the survival rate for these patients is only 55%. The overall 
survival for all neuroblastoma patients is about 70%. A better biological 
understanding is required to develop novel targeted therapy that may improve the 
outcome for cancer patients. Therefore we need to search for additional targets for 
therapeutic interventions in neuroblastoma.  
Inflammatory cells and mediators are important constituents of the local 
tumor environment that drives tumor progression. Treatment that inhibits 
inflammation can reduce tumor growth. Neuroblastoma cells are enriched in 
arachidonic acid, a pro-inflammatory omega-6 fatty acid, but deficient in anti-
inflammatory omega-3 fatty acids. We have previously shown that neuroblastoma 
expresses high levels of cyclooxygenase-2 (COX-2), which converts arachidonic 
acid into prostaglandins and that treatment with COX inhibitors reduces 
neuroblastoma tumor growth. In this thesis, I have investigated the role of 
arachidonic acid-derived metabolites in cancer, with a special focus on 
neuroblastoma.  
To understand the significance of a high COX-2 expression in neuroblastoma 
we investigated the role of prostaglandin E2 (PGE2), its pro-inflammatory 
metabolite. Neuroblastoma cells produce PGE2 and express all four PGE2 
receptors. PGE2 stimulates neuroblastoma cell growth, and inhibition of PGE2 
receptor signaling reduces cell survival. We also evaluated the potential of a more 
specific targeting of the COX-2 pathway to reduce PGE2 production by inhibition 
of microsomal prostaglandin E synthase-1 (mPGES-1). Downregulation of 
mPGES-1 expression reduces the clonogenic capacity and the tumorigenic 
potential of prostate and lung cancer cells.       
Another route for arachidonic acid metabolism is the 5-lipoxygenase (5-LO) 
pathway and the production of pro-inflammatory leukotrienes. We detected 
expression of all the enzymes that are required for leukotriene biosynthesis in 
neuroblastoma tumors and cell lines. Neuroblastoma cells produce leukotrienes that 
promote cell growth and survival. Treatment with 5-LO pathway inhibitors or 
leukotriene receptor antagonists induced apoptosis of neuroblastoma cells.    
Very little is known about the role of inflammation in childhood cancers. We 
show here a progressive inflammatory tumor microenvironment that parallels 
neuroblastoma tumor growth in the transgenic TH-MYCN model of 
neuroblastoma. Treatment with a low dose of anti-inflammatory acetylsalicylic acid, 
aspirin, modulates inflammatory parameters and significantly reduces tumor 
growth.  
In summary, this thesis shows that PGE2 and the leukotrienes act as autocrine 
and/or paracrine growth and survival factors in neuroblastoma. This suggests that 
inhibition of PGE2 and leukotriene signaling may represent novel targeted therapy 
for neuroblastoma.   
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1 INTRODUCTION  
 
1.1 CANCER 
In Sweden, over 50.000 adults and approximately 300 children are diagnosed 
with cancer every year. For both patient groups, cancer is the second most 
common cause of death in Sweden (www.Barncancerfonden.se; 
Cancerfondsrapporten, 2009). Cancer is the common name for a highly 
heterogeneous group of diseases that are all named after the tissue from 
which they arise, and a tumor may originate from almost any of the different 
cell types in the body. The common features for all solid tumors are 
uncontrolled cell growth, formation of new blood vessels, an ability to invade 
adjacent tissues, and metastatic potential (Hanahan and Weinberg, 2011).  
 
Children and adults develop different types of cancer. Adults predominantly 
develop cancers from mature tissues of an epithelial origin. The tumors 
develop over a long time period and acquire many genetic aberrations that 
result in uncontrolled cell growth. Childhood tumors have a much shorter 
latency and result from a disruption of normal development. These tumors 
arise in an immature tissue microenvironment, and they have fewer genetic 
aberrations and a different biology (Scotting et al., 2005; Grimmer and Weiss, 
2006; Johnsen et al., 2009). The current treatment modalities for both 
children and adults include radiation, surgery, and chemotherapy, and the 
importance of each of these treatments varies depending on the tumor type 
and stage of the disease. 
 
 
1.1.1 Neuroblastoma 
Neuroblastoma is a childhood tumor of the sympathetic nervous system, and 
in Sweden, 10-20 children are diagnosed with a neuroblastoma every year 
(Gustafsson et al., 2007b; Träger, 2009). The median age at diagnosis is 18 
months, and almost all patients are diagnosed before the age of four 
(Gustafsson et al., 2007b). The cause of neuroblastoma is largely unknown, 
and a family history of the disease exists in only 1-2% of the cases. Germline 
mutations have been discovered in two different genes, the paired-like 
homeobox 2B gene (PHOX2B; Trochet et al., 2004) and the anaplastic 
lymphoma kinase gene (ALK; Mosse et al., 2008), and these mutations explain 
most of the hereditary cases.  
   
Neuroblastoma tumors arise from sympathetic neural pre-cursor cells, the 
neural crest cells. The neural crest is a transient multipotent population of 
cells derived from the ectoderm that forms at the top of the neural tube, the 
structure that will become the spinal cord. The neural crest cells migrate 
throughout the embryo and differentiate to give rise to most of the cells of 
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the peripheral nervous system, the enteric nervous system, and cells of the 
craniofacial skeleton, as well as pigment cells, Schwann cells, and adrenal 
medullary cells (Jiang et al., 2011). Neuroblastoma tumors can arise anywhere 
along the sympathetic axis, but most primary tumors arise in the abdomen, 
and they most frequently occur in the adrenal medulla (Figure 1; Brodeur, 
2003). 
 
The clinical behavior of neuroblastoma is very heterogeneous. A small subset 
of tumors spontaneously regresses or matures without any treatment, 
whereas others do not respond to intensive multimodal treatment. A number 
of biological and clinical features are used to predict both the behavior of the 
tumor and the patient outcome. These factors include local or metastatic 
disease, age at diagnosis, histology, grade of tumor differentiation, 
amplification of the oncogene MYCN, genetic loss of chromosome 11q, and 
the tumor cell DNA ploidy. Using these factors, patients are classified into 
different risk groups according to the International Neuroblastoma Risk 
Group Staging System (INRGSS; Cohn et al., 2009). Patients are categorized 
into low-, intermediate-, or high-risk groups, and receive different treatments 
depending on their risk group. High-risk patients are treated with an intensive 
therapy that includes induction chemotherapy, surgery, myeloblative 
chemotherapy, stem cell rescue, and irradiation, followed by maintenance  
 
Figure 1. 
Neuroblastoma primary 
tumors derived from the 
neural crest arise in the 
sympathetic nervous 
system including the 
adrenal medulla, 
sympathetic ganglia and 
paraganglia. 
Neuroblastomas mainly 
metastasize to lymph 
nodes, bone and bone 
marrow, and in infants 
also spread to liver and 
subcutaneous tissue.  
 
Reprinted with 
permission from 
Springer Science media 
and Business Media, 
(Johnsen et al., 2009).  
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therapies consisting of retinoic acid in combination with immunotherapy, 
with monoclonal antibodies targeting disialganglioside 2 (GD2). Patients in 
the intermediate-risk group receive a milder therapy consisting of limited 
chemotherapy and surgery, and some of these patients also receive treatment 
with irradiation and retinoic acid. Low-risk patients may be cured by local 
surgery alone, and for the special form of metastatic neuroblastoma that can 
spontaneously regress, no treatment may be needed (Brodeur, 2000). Despite 
advances in the treatment of neuroblastoma, the overall survival rate for 
neuroblastoma patients in Sweden today is 74%, with a survival rate of only 
55% for patients in the high-risk group (Träger, 2009) 
 
 
1.2 EICOSANOIDS AND ARACHIDONIC ACID 
Eicosanoids are small, short-lived, fatty acid-derived signaling molecules. 
Eicosa is the Greek word for 20, and all eicosanoids consist of a 20-carbon 
backbone with different numbers and positions of the carbon-carbon double 
bonds and various side chains. Due to its high abundance, the predominant 
precursor of the eicosanoids is the polyunsaturated fatty acid arachidonic acid 
(20:4, ω6). Arachidonic acid is formed from the essential fatty acid linoleic 
acid (18:2, ω6) by a multi-stage process that includes desaturation by ∆6 and 
∆5 desaturases, which remove hydrogen atoms and create double bonds, and 
an elongation of two more carbon atoms by elongase (Schmitz and Ecker, 
2008). Arachidonic acid is stored in an esterified form in the phospholipids of 
cellular membranes (Schmitz and Ecker, 2008). The concentration of free 
non-esterified arachidonic acid is very low in the cell (Irvine, 1982), but is 
increased when arachidonic acid is released by cytosolic phospholipase A2 
(cPLA2; Haeggstrom and Funk, 2011; Murakami et al., 2011). Due to its 
importance in eicosanoid biosynthesis, the activity of cPLA2 is strictly 
regulated. It is activated by a calcium-dependent translocation from the 
cytoplasm to the perinuclear membrane (Clark et al., 1991), and at the 
membrane the hydrolytic activity is regulated by phosphorylation and by 
phosphatidylinositol-4,5-bisphosphate, PIP2 (Tucker et al., 2009). Free 
arachidonic acid is rapidly converted to eicosanoids by the enzymes 
cyclooxygenase (COX), lipoxygenase (LO), and cytochrome p450 (Figure 2). 
The metabolism of arachidonic acid by these pathways generates eicosanoids 
including prostaglandins (PGs), leukotrienes (LTs), lipoxins, 
hydroxyeicosatetraenoic acids (HETEs), hydroperoxyeicosatetraenoic acids 
(HpETEs), and epoxyeicosatrienoic acids (EETs).  
 
Arachidonic acid is not the only substrate for eicosanoid biosynthesis. 
Generally, eicosanoids formed from arachidonic acid are pro-inflammatory, 
while those formed from the omega-3 fatty acids, docosahexaenoic acid 
(DHA) or eicosapentaenoic acid (EPA), are anti-inflammatory. However, a 
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notable exception to this simplistic view is the anti-inflammatory lipoxins, 
which are formed from arachidonic acid. 
  
 
 
 
Figure 2. Schematic illustration of arachidonic acid metabolism. Arachidonic 
acid is released from membrane phospholipids by cytosolic phospholipase A2 
(cPLA2). Free arachidonic acid is rapidly converted by cyclooxygenases (COXs) 
into the prostaglandins, thromboxanes and prostacyclin, by the lipoxygenases (LOs) 
to leukotrienes, hydroxyeicosatetraenoic acids (HETEs) and lipoxins, or by 
cytochrome p450 into epoxyeicosatrienoic acids (EETs). 
 
 
1.3 THE CYCLOOXYGENASE PATHWAY  
Cyclooxygenases catalyze the conversion of arachidonic acid to (PGs) of the 
2-series, thromboxane A2 (TXA2), and prostacyclin (PGI2). PGs are involved 
in many processes in the body, such as pain, fever, and inflammation. PGs 
can be formed by most cells in the body. They are very short-lived and 
cannot be stored, but are synthesized de novo upon activation (Curtis-Prior, 
2004). 
 
 
1.3.1 Cyclooxygenases and prostaglandin biosynthesis  
Two cyclooxygenase isoforms exist, COX-1 (DeWitt and Smith, 1988; Merlie 
et al., 1988) and COX-2 (Xie et al., 1991), both of which catalyze the same 
reaction, though they differ in tissue distribution and function. COX-1 is 
constitutively expressed in many tissues to maintain housekeeping functions 
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and homeostasis. In contrast, COX-2 is not expressed in most organs under 
basal conditions, except for the brain, kidney, colon, testis, and female 
reproductive organs, but the expression can be induced by mitogenic and 
inflammatory stimuli (Zidar et al., 2009). The conversion of arachidonic acid 
by COX actually consists of two sequential activities in the same enzyme but 
at two distinct sites. In the first step, the cyclooxygenase active site removes 
two molecules of oxygen from arachidonic acid, leading to the formation of 
the cyclic endoperoxide PGG2, which in the next step is reduced to PGH2 by 
the peroxidase active site (Curtis-Prior, 2004). PGH2 is further metabolized 
into PGE2, PGD2, PGF2α, TXA2, and PGI2 by specific synthases (Figure 3).  
 
 
 
 
Figure 3. The COX pathway. COX-1 and COX-2 oxygenate arachidonic acid to 
form PGG2, which is further reduced to PGH2. PGH2 is highly unstable and is 
rapidly converted by specific synthases to PGE2, PGF2α, PGD2, PGI2 and TXA2. 
PGI2 and TXA2 have a very short half-life and are rapidly hydrolyzed to the inactive 
compounds 6-keto-PGF1α, and TXB2, respectively. Reprinted with permission from 
The FASEB Journal. Modified from (Romano and Claria, 2003). 
 
PGE2 synthases catalyze the isomerization of the endoperoxide moiety of 
PGH2 into a keto group at carbon 9 and a hydroxyl group at carbon 11 to 
form PGE2. Three enzymes with PGE2 synthases activity have been 
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described in the literature; two membrane-bound enzymes and one cytosolic 
enzyme. Microsomal prostaglandin E synthase 1 (mPGES-1) is a glutathione-
dependent, membrane-bound enzyme (Jakobsson et al., 1999) that is 
suggested to predominantly couple with COX-2 (Murakami et al., 2000; 
Thoren and Jakobsson, 2000). mPGES-1 is constitutively expressed in the 
placenta, prostate, testis, mammary gland, and bladder, but is normally absent 
or expressed at low levels in other tissues (Jakobsson et al., 1999). As for 
COX-2, the expression can be induced by inflammatory stimuli (Jakobsson et 
al., 1999; Murakami et al., 2000). Mice deficient in mPGES-1 confirm the 
importance of this enzyme for the in vivo production of PGE2, and indicate a 
role for this enzyme in both acute and chronic inflammatory reactions 
(Trebino et al., 2003). The two other synthases, mPGES-2 (Tanikawa et al., 
2002) and cycosolic PGE synthase (cPGES; Tanioka et al., 2000), can convert 
PGH2 into PGE2 in vitro, but studies using knockout mice indicate that these 
synthases may not be essential for production in vivo (Lovgren et al., 2007; 
Jania et al., 2009). However, the production of PGE2 can still be detected in 
mice lacking mPGES-1, thus supporting the hypothesis that additional 
pathways are involved in the production.  
 
Specific enzymes that catalyze the conversion of PGH2 to PGD2, PGF2α, 
TXA2, and PGI2 have also been identified. The chemical structure of PGD2 is 
very similar to PGE2, with the only difference being that the keto group and 
the hydroxyl group are in opposite positions. Two enzymes are responsible 
for the isomerization of PGH2 to PGD2, lipocalin-type and haematopoetic 
PGD synthase. PGF2α can be formed by the reduction of PGH2 by 9,11-
endoperoxide reductase or by a reduction of PGE2 or PGD2 by keto 
reductases. In addition, thromboxane synthase and prostacyclin synthase 
catalyze the synthesis of TXA2 and PGI2, respectively (Curtis-Prior, 2004). 
 
Once the PGs have been synthesized, they are transported out of the cell into 
the extracellular matrix. Studies have shown that PGs can be effluxed by 
simple diffusion (Chi et al., 2006) and/or actively transported by multidrug 
resistance-associated proteins (MRP; Fletcher et al., 2010). However, the 
contribution and relative importance of each of these two routes is not yet 
known. 
 
 
1.3.2 Prostaglandin E2 signaling and biological effects 
PGs, TXA2, and PGI2 are potent hormone-like, short-lived mediators that act 
near their site of synthesis in a paracrine and autocrine manner. They mediate 
their signals by binding to specific G-protein coupled receptors (GPCRs) that 
are named after the ligand bound into EP, DP, FP, IP, and TP (Woodward et 
al., 2011). GPCRs are found in cellular membranes, and they all share the 
structure of seven-transmembrane α-helices that weave in and out of the 
membrane. When a ligand binds to the receptor, it causes a conformational 
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change that activates a G-protein trimer. The G-protein trimer consists of an 
α, β, and γ subunit. Upon activation, the Gα subunit dissociates from the Gβγ 
subunit complex, which can then stimulate downstream effectors. Further 
signal transduction is primarily dependent on the type of the Gα subunit 
(Dorsam and Gutkind, 2007).  
 
PGE2 is an important actor in and regulator of both pro- and anti-
inflammatory immune responses, though it also has a broad range of other 
biological activities (Hirata and Narumiya, 2011). PGE2 exerts its actions by 
binding to four different receptor subtypes, designated EP1, EP2, EP3, and 
EP4. One single cell can express one or more of these receptors. PGE2 
binding to the EP1 receptor leads to an increased intracellular calcium level. 
The EP1 receptor has a prominent role in pain perception and stress, but is 
also expressed and participates in the physiological functions of the lungs, 
stomach, and kidneys. Activation of both the EP2 and EP4 receptors results 
in elevated cyclic adenosine monophosphate (cAMP) levels. The two 
receptors can act in concert, but also mediate receptor-specific effects. The 
EP2 receptor is widely distributed in the body and mediates a broad range of 
actions, including bronchodilatory and tocolytic effects, neuroprotection, and 
neurotoxicity. Similarly, the EP4 receptor exhibits a wide tissue distribution, 
and is primarily involved in cardiovascular biology and bone metabolism. The 
EP3 receptor has several splice variants capable of coupling to different G-
proteins, thereby contributing to the wide spectrum of EP3 actions; however, 
the majority of the isoforms act to inhibit cAMP production. This receptor 
mediates the fever response, and is involved in pain perception and labor 
(Woodward et al., 2011). 
 
 
1.3.3 Termination of prostaglandin E2 signaling 
The catabolism and termination of PGE2 signaling occur in two steps 
(Nomura et al., 2004). In the first step, PGE2 is actively transported from the 
extracellular milieu into the cytoplasm by the prostaglandin transporter (PGT; 
Chi et al., 2006). In the second step, PGE2 is rapidly inactivated through 
oxidation of the hydroxyl group at carbon 15 to 15-keto PGE2 by 15-
hydroxyprostaglandin dehydrogenase (15-PGDH). Both PGT (Lu et al., 1996) 
and 15-PGDH (Tai et al., 2002) are ubiquitously expressed in mammalian 
tissues.  
 
 
1.3.4 The cyclooxygenase pathway in cancer 
The expression of COX-2 is upregulated in pre-malignant lesions such as 
gastric dysplasia (Thiel et al., 2011) colorectal adenoma, prostatic 
intraepithelial neoplasia, carcinoma in situ, chronic hepatitis, and Barrett’s 
esophagus (de Groot et al., 2007). COX-2 is also overexpressed in malignant 
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tissues of various origins, in invasive cancers, and at metastatic sites (Harris, 
2009). Increased PGE2 levels are frequently found in pre-malignant and 
malignant tissues (McLemore et al., 1988; Pugh and Thomas, 1994; Freedman 
et al., 2007) and in the urine of cancer patients (Johnson et al., 2006; 
Kekatpure et al., 2009). Moreover, a high expression of COX-2 (Harris, 2009; 
Thiel et al., 2011) and increased PGE2 levels (Rolland et al., 1980; Kekatpure et 
al., 2009) have been associated with a poor prognosis. In the pediatric age 
group, COX-2 is upregulated in neuroblastoma (Johnsen et al., 2004), brain 
tumors (Patti et al., 2002; Baryawno et al., 2008), and sarcomas (Dickens et al., 
2002).    
  
Most research has focused on the role of COX-2 in cancer, although COX-1, 
which is thought to mainly be involved in housekeeping functions, has also 
been shown to be overexpressed in breast (Hwang et al., 1998), ovarian 
(Gupta et al., 2003; Freedman et al., 2007) and cervical tumor tissues (Sales et 
al., 2002).  
  
Many mechanisms underlie the tumor-promoting effects of PGE2 (Wang and 
Dubois, 2010). First, PGE2 stimulates cell proliferation, increases cell 
survival, and inhibits apoptosis through the activation of pro-survival 
pathways such as phosphatidyl-inositol 3 kinase (PI3K)-Akt, extracellular 
signal-regulated kinase (Erk), canonical wingless (Wnt), transactivation of the 
receptor for epidermal growth factor (EGFR), and the upregulation of anti-
apoptotic Bcl-2 (Wang and Dubois, 2010). Second, PGE2 stimulates cell 
migration (Sheng et al., 2001) and invasion by upregulation of the chemokine 
receptor CCR7 (Pan et al., 2008), activation of Rap signaling (Wu et al., 2011), 
and transactivation of EGFR (Buchanan et al., 2006). Furthermore, PGE2 
increases adhesion by enhancing the expression of integrin α3β1 (Mitchell et 
al., 2010), and mediates breakdown of the extracellular matrix by increasing 
matrix metalloproteinase-2 production (Ito et al., 2004). PGE2 supports 
angiogenesis by inducing the expression of vascular endothelial growth factor 
(VEGF; Sonoshita et al., 2001; Chang et al., 2004) and the chemokine (C-X-C 
motif) ligand 1 (Wang et al., 2006). In addition, PGE2 is a key mediator in the 
crosstalk between tumor cells and stromal cells in the tumor 
microenvironment, and PGE2 contributes to the creation of a tumor 
promoting-inflammatory microenvironment and suppresses activation of the 
immune system (Wang and Dubois, 2010). 
 
 
1.3.5 Nonsteroidal anti-inflammatory drugs (NSAIDs)  
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used in the 
treatment of pain, fever, and inflammation. Their basic mode of action is to 
inhibit the COX enzymes, thereby reducing the production of PGs that are 
critically involved in these reactions. NSAIDs are a structurally diverse group 
of compounds that include salicylates, proprionic acids, pyrazoles, acetic 
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acids, oxicams, fenamates, naphthyl-alkanones, and coxibs (Reuben, 2007). 
They are called nonsteroidal to distinguish them from steroids, which also 
reduce eicosanoid production and have anti-inflammatory properties. 
 
Traditional NSAIDs are dual inhibitors of both COX-1 and COX-2. With 
the increasing use of these medications, serious adverse gastrointestinal side 
effects became evident. These effects mainly occurred due to the inhibition 
of PGs produced by COX-1 that protect the gastric mucosa (Ong et al., 
2007). To avoid the adverse effects of traditional NSAIDs, specific COX-2 
inhibitors, called coxibs, were developed. The existence of an extra side 
pocket in the active site of COX-2 made this possible. However, although the 
use of coxibs reduced the gastrointestinal complications, these compounds 
proved to have other side effects—most seriously, an increased risk for 
cardiovascular events—that lead to the withdrawal of rofecoxib (Vioxx) in 
2004 (Bresalier et al., 2005). Coxibs are thought to shift the balance between 
TXA2 and PGI2 that maintains cardiovascular homeostasis. Specifically, 
coxibs inhibit the production of anti-thrombotic PGI2 by COX-2 in vascular 
endothelial cells without changing the synthesis of pro-thrombotic TXA2 
from COX-1 activity in platelets (Cheng et al., 2002).  
 
1.3.5.1 Acetylsalicylic acid 
The history of acetylsalicylic acid (ASA), or aspirin, goes back to early herbal 
folklore and the use of willow bark and meadowsweets to relieve pain and 
fever; however, its molecular mechanism was not uncovered until 1971 (Vane 
and Botting, 2003). ASA belongs to the salicylate group of traditional 
NSAIDs. In contrast to the other NSAIDs, ASA irreversibly inhibits the 
COX enzymes by covalent modifications (Curtis-Prior, 2004). ASA acetylates 
COX-1 at serine 530, which prevents arachidonic acid from entering the 
active site and thus inhibits PG biosynthesis. In addition, ASA acetylates 
COX-2 at homologous serine 516, which changes the enzymatic activity so 
that arachidonic acid is instead converted to 15-hydroxyeicosatetraenoic acid 
(15R-HETE). 15R-HETE can further be converted to anti-inflammatory 
lipoxins and resolvins (Claria and Serhan, 1995; Chiang et al., 2004; Serhan et 
al., 2008). 
 
 
1.3.6 NSAIDs in cancer therapy 
In 1988, an epidemiologic study revealed that colorectal cancer patients were 
less likely than controls to have used aspirin in the past (Kune et al., 1988). 
Ever since, numerous studies have evaluated the effect of NSAIDs in cancer 
prevention. These studies show an indisputable promise in using NSAIDs as 
chemopreventive agents in various adult cancers, though they have also 
raised serious concerns about NSAIDs’ adverse side effects. Most of these 
adverse complications are likely due to on-target effects; however, these 
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effects also depend on dosage. Epidemiologic studies show that a low-dose 
(75-300 mg) ASA is as effective as a higher dose (≥500mg) ASA and reduces 
the incidence of colorectal (Rothwell et al., 2010) and prostate cancer (Salinas 
et al., 2010), while also reducing the risk of cancer-related death (Rothwell et 
al., 2011). 
 
NSAIDs can also reduce tumor growth of already established tumors by 
inhibiting the tumor-promoting actions of PGE2. Treatment with NSAIDs 
induces apoptosis (Johnsen et al., 2004), reduces angiogenesis and metastatic 
spread (Masferrer et al., 2000; Kakiuchi et al., 2002), and abrogates PGE2-
induced immunosuppression (Stolina et al., 2000; Lonnroth et al., 2008). 
NSAIDs can also potentiate the toxic effect of cytostatic drugs and protect 
against chemotherapy-associated side effects (de Groot et al., 2007). Even so, 
many NSAIDs and coxibs have off-target effects that may contribute to their 
cytotoxic and anti-tumorigenic potential (Fischer et al., 2011). 
 
In neuroblastoma, treatment with NSAIDs results in reduced tumor growth 
by the induction of apoptosis through modulation of the expression of p73 
isoforms (Lau et al., 2009) and cleavage of caspase-9 and -3 and PARP 
(Johnsen et al., 2004; Parashar and Shafit-Zagardo, 2006). Moreover, NSAIDs 
inhibit angiogenesis (Ponthan et al., 2007) and potentiate the effect of 
cytostatic drugs on neuroblastoma (Lau et al., 2007; Ponthan et al., 2007). 
 
 
1.4 THE 5-LIPOXYGENASE PATHWAY 
Lipoxygenases (LO) are a family of iron-containing enzymes that catalyze the 
peroxidation of polyunsaturated fatty acids to hydroperoxy derivatives. They 
are named after the carbon atom of arachidonic acid to which oxygen is 
added. Three main types of LOs exist in humans: 5-LO, 12-LO, and 15-LO 
(Haeggstrom and Funk, 2011). The oxygenation of arachidonic acid by the 
LOs leads to the production of 5-, 12- and 15-HpETE, respectively, which 
can be further metabolized into LTs, hepoxilins, lipoxins, and HETEs 
(Samuelsson et al., 1987). 5-LO catalyzes the initial steps in the formation of 
LTs and lipoxins (Figure 4).  
 
 
1.4.1 5-Lipoxygenase and the leukotrienes 
5-LO is primarily expressed in various leukocytes such as B-lymphocytes, 
dendritic cells, monocytes/macrophages, mast cells, neutrophils, and 
eosinophils (Radmark and Samuelsson, 2009). In resting cells, 5-LO resides in 
the cytoplasm or nucleoplasm and translocates upon calcium activation to the 
perinuclear membrane. The nuclear redistribution of 5-LO is regulated by 
phosphorylations (Radmark et al., 2007), and in vitro, 5-LO is phosphorylated 
by the MAPK-activated protein kinase 2 at Ser-271 (Werz et al., 2002b), by 
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Erk2 at Ser-663 (Werz et al., 2002a) and by protein kinase A at Ser-523 (Luo et 
al., 2004). At the nuclear membrane, 5-LO co-localizes with cPLA2 and 5-
lipoxygenase activating protein (FLAP; Dixon et al., 1990). FLAP is a small 
integral nuclear membrane protein that is required for LT biosynthesis, but 
does not have enzymatic activity and was recently suggested to act as a 
scaffold protein for 5-LO (Mandal et al., 2008). Subsequently, in a two-step 
reaction, 5-LO catalyzes the oxygenation of arachidonic acid at C-5 to 5-
hydroperoxytetraenoic acid (5-HpETE) and the further dehydration to 
 
 
 
 
Figure 4. The 5-LO pathway. 5-LO catalyzes the oxygenation of arachidonic acid 
to 5(S)-HpETE. 5(S)-HpETE can be reduced to 5(S)-HETE or subjected to the 
stereospecific removal of the pro-R hydrogen at carbon-10 to generate the highly 
unstable LTA4. LTA4 is either hydrolyzed to LTB4 by LTA4 hydrolase or converted 
into LTC4 by addition of the peptide glutathione by LTC4 synthase. LTC4 can 
undergo further metabolism through a series of peptidic cleavage reactions to yield 
LTD4 and LTE4. Reprinted with the permission from FASEB journal. Modified 
from (Romano and Claria, 2003). 
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the epoxide LTA4 (Samuelsson et al., 1987). An alternative fate for 5-HpETE 
is to be metabolized to 5-HETE, 5-oxo-ETE, and lipoxins (Radmark et al., 
2007). The instable intermediate LTA4 can be metabolized by two routes: 
enzyme leukotriene A4 hydrolase (LTA4H) to LTB4 or leukotriene C4 
synthase (LTC4S) to LTC4.  
 
LTA4H is a soluble protein that resides in the cytosol, although a nuclear 
localization has also been reported (Brock et al., 2001). In contrast to 5-LO, 
LTA4H has a wide tissue and cellular distribution, and is particularly 
expressed in the intestine, spleen, lung, and kidney, in addition to its 
expression in various blood cells (Haeggstrom, 1999). LTA4 can also be 
conjugated with glutathione by LTC4S to form the cysteinyl containing LTC4, 
which is the parent compound of the cysteinyl leukotrienes (CysLTs) LTD4 
and LTE4. LTC4S is an integral membrane protein that is located in the outer 
nuclear membrane (Christmas et al., 2002), and the expression of LTC4S is 
restricted to basophils, eosinophils, mast cells, monocytes/macrophages, and 
platelets (Lam and Austen, 2002). LTC4 is secreted from the cell by MRP1 
and -4 (Leier et al., 1994; Wijnholds et al., 1997). Once transported to the 
extracellular space, γ-glutamyl transdipepdidase cleaves the glutamic moiety 
to form LTD4, which can be further metabolized by cleavage of the glycine 
moiety by a dipepdidase enzyme to LTE4 (Hammarstrom et al., 1985).  
 
LTs can also be produced by transcellular metabolism. In that case, the LTA4 
that is produced in one cell is transferred to another cell that further 
metabolizes LTA4 into LTs (Dahinden et al., 1985; McGee and Fitzpatrick, 
1986; Fabre et al., 2002; Zarini et al., 2009). This process explains the evidence 
that LTA4H and LTC4S are expressed in many cell types that do not express 
5-LO. 
 
 
1.4.2 Leukotriene signaling and biological effects 
The name “leukotriene” comes from the words “leukocyte” and treien: 
“leukocyte” because they were first found in leukocytes, and treien because 
they all contain three conjugated double bonds in their chemical structure. 
LTs are predominantly produced by leukocytes, and they mediate their effects 
by binding the G-protein coupled LT receptors, which are subdivided into 
the LTB4 receptors (BLT) and the CysLT receptors. LTs are very potent pro-
inflammatory molecules that can mediate both short-term effects and long-
term effects on transcription.   
 
1.4.2.1 Leukotriene B4  
The effect of LTB4 is mediated through activation of two different receptors: 
a high-affinity receptor named BLT1 (Yokomizo et al., 1997), and a lower-
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affinity receptor named BLT2 (Yokomizo et al., 2000). Human BLT1 and 
BLT2 are structurally similar, with a 45% amino acid sequence identity, 
though they differ in tissue and cell distribution (Yokomizo et al., 2000). 
BLT1 is primarily expressed on leukocytes, and is present at a low level in 
thymus and spleen (Yokomizo et al., 1997). The BLT2 receptor is more 
ubiquitously expressed, with the highest expression in the spleen, ovary, liver, 
and leukocytes (Yokomizo et al., 2000). In addition, ligands other than LTB4 
can bind to and activate the BLT2 receptor (Okuno et al., 2008). Both BLT1 
and BLT2 couple to intracellular G-proteins that mediate an intracellular 
increase in calcium and a reduced level of cAMP (Yokomizo et al., 2000; 
Toda et al., 2002). In addition to BLT1 and BLT2, LTB4 also binds to a 
nuclear receptor, peroxisome proliferator-activated receptor α, or PPARα. 
This receptor activates the transcription of genes involved in lipid 
metabolism and inflammation (Devchand et al., 1996; Narala et al., 2010). 
 
LTB4 is a very potent chemoattractant factor for leukocytes. It promotes 
leukocyte recruitment to sites of inflammation by stimulating migration and 
enhancing the adherence of leukocytes to the blood vessel wall, which is a 
prerequisite for migration into the tissue (Ford-Hutchinson et al., 1980; Smith 
et al., 1980; Goodarzi et al., 2003; Tager et al., 2003; Lundeen et al., 2006; Del 
Prete et al., 2007). Once the leukocytes reach the inflamed site, LTB4 
promotes leukocyte activation and proliferation and cell survival (Peters-
Golden et al., 2005; Kim and Luster, 2007). In addition to its chemotactic 
properties, LTB4 plays an important role in the body’s defense against 
pathogens by augmenting neutrophil and macrophage phagocytosis and 
bactericidal activity (Peters-Golden et al., 2005). LTB4 has also been 
implicated in various inflammatory diseases, autoimmune disorders and 
cardiovascular disease (Peters-Golden and Henderson, 2007). 
 
1.4.2.2 Cysteinyl leukotrienes, LTC4, LTD4, and LTE4 
Pharmacological studies have revealed the existence of two CysLT receptors, 
designated CysLT1 (Lynch et al., 1999) and CysLT2 (Heise et al., 2000). They 
are both high-affinity receptors that upon activation lead to an intracellular 
calcium mobilization and/or reduction in cAMP levels, but they differ in rank 
order potency of agonist activation. The rank order for CysLT1 is 
LTD4>>LTC4=LTE4 (Lynch et al., 1999), whereas for CysLT2 the rank order 
is, LTD4=LTC4>LTE4 (Heise et al., 2000). Nonetheless, significant evidence 
points to the existence of additional CysLT receptor subtypes that need 
further characterization (Singh et al., 2010; Haeggstrom and Funk, 2011). 
Both receptors are expressed in leukocytes, the spleen, and the lungs, 
although CysLT2 is also abundantly expressed in the heart, adrenal glands, 
and brain (Singh et al., 2010). 
 
CysLTs are potent mediators of bronchoconstriction (Dahlen et al., 1980), 
they increase vascular permeability (Dahlen et al., 1981) and promote mucous 
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secretion (Marom et al., 1982). They also mediate functions of the immune 
system, including the recruitment of eosinophils and monocytes/ 
macrophages towards sites of inflammation, the stimulation of cytokine and 
chemokine production, and the promotion of activation and maturation of 
eosinophils and dendritic cells (Kim and Luster, 2007). CysLTs also play a 
prominent role in asthma, and LT inhibitors are currently used in asthma 
treatment (Peters-Golden and Henderson, 2007).  
 
 
1.4.3 5-Lipoxygenase signaling pathway in cancer 
The importance of LOs in cancer has not been studied as extensively as that 
of the COX enzymes, and their role is more complex and includes both pro- 
and anti-tumorigenic LO isoforms. In general, 5-LO and 12-LO have pro-
tumorigenic effects, whereas 15-LO-2 has anti-tumorigenic effects and the 
role of 15-LO-1 is controversial (Wang and Dubois, 2010). Increasing 
evidence indicates that the pro-tumorigenic isoforms are preferentially 
expressed during cancer development, while the expression of anti-
tumorigenic isoforms is lost (Furstenberger et al., 2006). 
 
5-LO is expressed in early pre-malignant lesions of the pancreas (Hennig et 
al., 2005), colon (Melstrom et al., 2008), and esophagus (Chen et al., 2004), as 
well as in malignant tissues of various origin such as the brain (Boado et al., 
1992; Ishii et al., 2009), lungs (Avis et al., 1996), prostate (Gupta et al., 2001), 
pancreas (Hennig et al., 2002), colon (Ohd et al., 2003) and esophagus (Chen 
et al., 2004). A concomitant increased concentration of 5-LO products can be 
detected in cancer tissues (el-Hakim et al., 1990; Simmet et al., 1990; Larre et 
al., 2008), and many cancer cell lines are capable of producing LTs (Avis et al., 
1996).   
  
Mechanisms underlying the tumor-promoting effects of LTs are not fully 
understood. LTs have been shown to increase the proliferation of cancer cells 
through activation of the MEK/Erk and PI3K/Akt pathways (Tong et al., 
2005). Direct evidence that LTB4 promotes tumor growth comes from a 
study that shows that LTB4 increased the incidence, number, and volume of 
macroscopic oral tumors of DMBA-induced hamster cheek pouch 
carcinomas (Sun et al., 2006). 5-LO has also been documented to contribute 
to the production of reactive oxygen species (ROS) from arachidonic acid 
that can induce DNA damage and increase cell proliferation (Catalano et al., 
2005). Furthermore, the upregulation of 5-LO protects cancer cells from 
apoptosis induced by treatment with cytotoxic drugs and by the inhibition of 
p53 (Catalano et al., 2004).  
 
Therapeutic inhibition of key enzymes in the 5-LO pathway leads to an 
induction of apoptosis by downregulation of anti-apoptotic bcl-2, 
upregulation of pro-apoptotic bax (Avis et al., 2001; Tong et al., 2002; Lim et 
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al., 2010), inhibition of cell proliferation, and reduced tumor growth (Avis et 
al., 2001; Gunning et al., 2002; Chen et al., 2003; Melstrom et al., 2008). Similar 
to the NSAIDs, many of the compounds used to inhibit the 5-LO pathway 
and LT signaling have off-target effects at high doses that may contribute to 
anti-tumor activity (Fischer et al., 2010). One study has shown that the genetic 
deletion of 5-LO in the transgenic APC∆468 mice model of colon polyposis 
resulted in a reduced number and size of intestinal polyps, with a reduced 
proliferation and an increased apoptosis (Cheon et al., 2011). The study 
observed an even more pronounced effect when 5-LO was deleted only in 
hematopoietic cells, suggesting a paracrine effect wherein leukocytes produce 
LTs that potentiate the proliferation of intestinal epithelial cells (Cheon et al., 
2011). 
 
 
1.5 CANCER-RELATED INFLAMMATION  
Smoldering inflammation is an essential component of the tumor 
microenvironment, independent of the trigger for development that can 
contribute to all the hallmarks of cancer (Mantovani et al., 2008; Hanahan and 
Weinberg, 2011). It supplies the tumor cells with growth and survival factors 
that sustain proliferation and inhibit cell death. It promotes angiogenesis, 
invasion, and metastasis. Smoldering inflammation suppresses the initiation 
of adaptive immune responses that could potentially carry out surveillance 
and eradicate nascent tumors, and it also affects the tumor’s response to 
therapy (Mantovani et al., 2008; Hanahan and Weinberg, 2011). 
 
An inflammatory tumor microenvironment can be initiated by two different 
pathways: an extrinsic pathway or an intrinsic pathway (Mantovani et al., 
2008). The extrinsic pathway is driven by chronic inflammation and 
infections that increase the risk of developing certain cancers, while the 
intrinsic pathway is driven by oncogenes that activate transcriptional 
programs involved in inflammation.   
 
 
1.5.1 Tumor-infiltrating immune cells 
Various leukocytes of both the innate and adaptive immune system are 
frequently present within tumors (Mantovani et al., 2008). Many of these cells 
have an intrinsic ability to exert both pro- and anti-tumorigenic activities 
(Biswas and Mantovani, 2010; Grivennikov et al., 2010). The inflammatory 
tumor milieu attracts and induces both suppressive and pro-inflammatory 
immune cell phenotypes and guides their activities in favor of tumor growth 
and progression (Mantovani et al., 2008; Grivennikov et al., 2010). 
 
Key players in normal inflammatory responses and in cancer-related 
inflammation are the macrophages. Tumor-associated macrophages (TAM) 
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generally have a tolerant M2 phenotype that promotes tumor progression 
(Mantovani et al., 2008). TAM influences nearly all aspects of carcinogenesis 
and tumor growth, including increased genomic instability and cell 
proliferation, the promotion of angiogenesis and lymphangiogenesis, the 
degradation and remodeling of the extracellular matrix that facilitates 
migration, as well as invasion, metastasis, and suppression of adaptive 
immune responses (Biswas and Mantovani, 2010). The inflammatory tumor 
microenvironment also accumulates and activates myeloid-derived suppressor 
cells (MDSCs) and regulatory T cells (Treg) that strongly suppress innate and 
adaptive anti-tumor immunity, thereby facilitating tumor growth (Ostrand-
Rosenberg and Sinha, 2009; DeNardo et al., 2010). Additionally, tumors often 
contain small numbers of dendritic cells that are essential for the activation of 
T cells and adaptive immune responses against tumors. The dendritic cells 
within tumors usually have an immature phenotype that is unable to stimulate 
an anti-tumor response (Gabrilovich, 2004). Another important mechanism 
by which tumors subvert an effective anti-tumor response of the adaptive 
immune system is by inducing a T helper 2 (Th2)-type of response that 
suppresses cytotoxic T lymphocytes (CTL) responses in combination with an 
increased humoral immunity (Johansson et al., 2008).  
 
 
1.5.2 Inflammatory signaling molecules 
Cytokines, chemokines, and eicosanoids are important mediators involved in 
the crosstalk and reciprocal interactions between cancer cells and immune 
cells. These mediators are critically involved in the evolution of an 
inflammatory tumor microenvironment.  
 
1.5.2.1 Cytokines 
Cytokines are proteins that are involved in the regulation of  immune 
responses. By binding to cell surface receptors, they can alter the behavior 
and properties of  immune cells. Different cytokines can have pro-
inflammatory or anti-inflammatory effects, depending on the type of  cell 
interaction and other coexisting signaling molecules (Lin and Karin, 2007). 
The tumor microenvironment is often dominated by pro-inflammatory, 
immunosuppressive Th2 cytokines such as interleukin (IL)-1β, IL-4, IL-5, 
IL-6, IL-10, IL-13, and tumor necrosis factor α (TNFα; Dranoff, 2004) that 
induce programs promoting tumor progression. 
 
1.5.2.2 Eicosanoids 
PGE2 is a very powerful inflammatory mediator that contributes to the 
buildup of an inflammatory tumor microenvironment, and it is the only PG 
or LT that has a clear role in tumor immunosuppression (Wang and Dubois, 
2010). PGE2 can be produced by cancer cells and also by various immune 
cells such as macrophages, dendritic cells, and Treg cells (Harris et al., 2002). 
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One important function of PGE2 is the modulation of cytokine production. 
PGE2 enhances the production of Th2-type cytokines while inhibiting the 
production of anti-inflammatory cytokines (Harris et al., 2002).  
 
PGE2 can also exert a direct effect on various immune cells. It inhibits the 
anti-tumor activity of macrophages and favors an M2 polarization of TAM 
(Harris et al., 2002; Eruslanov et al., 2009). PGE2 attracts MDSCs and 
increases their suppressive activity (Sinha et al., 2007), and, by upregulation of 
the transcription factor FOXP3, PGE2 enhances the inhibitory function of 
Treg cells (Baratelli et al., 2005). PGE2 also decreases the number of tumor-
infiltrating dendritic cells (Ahmadi et al., 2008), prevents the differentiation 
and maturation of these cells, and downregulates antigen presentation and 
cross-presentation pathways (Yang et al., 2003; Ahmadi et al., 2008), resulting 
in an abrogated anti-tumor-specific CTL response (Ahmadi et al., 2008). 
Moreover, PGE2 directly inhibits the anti-tumor activity of CTLs (Zeddou et 
al., 2005) and natural killer cells (Joshi et al., 2001). PGE2 has also been 
demonstrated to promote the expansion of Th17 cells, which may contribute 
to inflammation and tumor growth (Wang and Dubois, 2010). 
 
The role of LTs in cancer-related inflammation has not been thoroughly 
studied, though as discussed above, LTs play an important role in normal 
inflammatory processes by increasing vascular permeability and attracting and 
activating leukocytes, and could potentially exert the same effects if present in 
the tumor microenvironment. In fact, one study shows that LTB4 attracts 
MDSCs to the tumor and increases their suppressive activity (Cheon et al., 
2011). 
 
Because of limitations in technology, very few studies have investigated the 
eicosanoid profile of the tumor microenvironment. One study measured the 
concentration of six different eicosanoids in ovarian cancer tissues, and only 
PGE2 was significantly more abundant in malignant tissues than in benign 
tissues (Freedman et al., 2007). The study also reported that the combined 
level of PGE2, 12-HETE, 5-HETE, and LTB4 increased during tumor 
progression. In contrast, no significant change was observed for 15-HETE 
and 13-HODE, which might suppress tumor growth. Another study 
examined the profile of LO-derived products during colorectal tumorigenesis 
(Shureiqi et al., 2010) and found a significant decrease in 13-HODE during 
tumor progression, though no change was found in 12-HETE, 15-HETE, or 
LTB4 levels. 
 
 
1.5.3 Neuroblastoma tumor microenvironment 
Neuroblastoma tumors contain infiltrating monocytes/macrophages that 
contribute to cell proliferation and growth. Expression of TAM markers such 
as CD14, CD16, IL-6, the IL-6 receptor, and TGF-β in primary high-risk 
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neuroblastoma tumors are inversely correlated with a five-year, event-free 
survival (Song et al., 2009). TAM stimulate neuroblastoma proliferation, at 
least in part by the production and release of IL-6 (Song et al., 2009). The 
cytokine IL-6 appears to play an important role in neuroblastoma (Pistoia et 
al., 2011). IL-6 helps to promote neuroblastoma growth, protects cells from 
drug-induced apoptosis, and has been implicated in bone invasion and 
metastasis (Ara et al., 2009; Song et al., 2009). High-risk neuroblastoma 
patients with bone marrow metastasis show an increased level of IL-6 in both 
serum and bone marrow compared to normal patients (Ara et al., 2009). In 
comparison with other cytokines, IL-6 is expressed at moderate levels in 
primary neuroblastoma tumors that express large amounts of IL-8, IL-13, 
interferon γ (IFNγ), and TNFα, but relatively low levels of the typical Th2 
cytokines IL-4, IL-5, and IL-10 (Carlson, 2011). In addition, neuroblastoma 
cells ubiquitously express high concentrations of the ganglioside GD2, which 
directly inhibits dendritic cell differentiation and activation (Redlinger et al., 
2004).  
 
Quite a bit of research has focused on the potential of immunotherapy in 
neuroblastoma (Seeger, 2011). Recently, a phase III study showed an 
improved outcome for high-risk neuroblastoma patients when an anti-GD2 
monoclonal antibody, in combination with IL-2 and granulocyte-macrophage 
colony-stimulating factor GM-CSF, was added to the standard retinoic acid 
maintenance therapy (Yu et al., 2010).  
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2 AIMS 
Neuroblastoma cells are enriched in arachidonic acid (Reynolds et al., 2001) 
and overexpress COX-2 (Johnsen et al., 2004), but are deficient in the anti-
inflammatory fatty acid DHA. The purpose of this thesis was to further 
investigate the role of arachidonic acid-derived eicosanoids in cancer, 
particularly in neuroblastoma.  
 
The specific aims of this thesis were: 
 
• To determine whether the COX metabolite PGE2 and its receptors are 
important for neuroblastoma cell survival and proliferation.  
 
• To determine whether mPGES-1 is expressed in prostate cancer and 
whether knockdown of mPGES-1 could prevent tumor growth.   
 
• To determine whether neuroblastoma cells express 5-LO and the 
leukotriene receptors and investigate the importance of leukotrienes 
for neuroblastoma cell survival. 
 
• To characterize the tumor microenvironment of transgenic TH-
MYCN neuroblastoma tumors to determine the composition and 
dynamics of immune cells during tumor progression. 
 
• To investigate the expression of COX-1 and COX-2 and the effect of 
a low-dose ASA treatment on the composition of immune cells in TH-
MYCN tumors.  
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3 METHODS  
 
3.1 PATIENT MATERIAL 
3.1.1 Human tissue samples 
3.1.1.1 Neuroblastoma tissue samples 
All neuroblastoma tissue samples were collected at the Astrid Lindgren 
Children’s Hospital. The diagnoses were established in standard of care, 
which includes careful histological and biological assessments. Patient and 
tumor characteristics are summarized in table I in paper III. Ethical approval 
was obtained from the Karolinska University Hospital research ethics 
committee and the Stockholm regional ethics committee. 
 
3.1.1.2 Prostate tumor tissue samples 
The prostate tumor tissue samples were collected at the Karolinska 
University Hospital. The diagnoses were established in standard of care, and 
the patient and tumor characteristics are summarized in table I in paper II. 
Ethical approval was obtained from the Karolinska University Hospital 
research ethics committee and the Stockholm regional ethics committee.  
 
 
3.1.2 Human cell lines 
The neuroblastoma cell lines used are all derived from high-risk patients with 
tumors having different genetical and biological characteristics. The panel of 
cell lines used is as follows: IMR-32, SK-N-AS, SK-N-BE(2), SK-N-DZ, SK-
N-FI, SK-N-SH, and SH-SY5Y. The myelocytic cell line U-937 was used for 
control purposes. In paper II, prostate cancer cell lines DU145, PC3, and 
LNCaP and the non-small lung cancer cell line A549 were used. Cells were 
cultured in Eagle´s MEM (SH-SY5Y), Ham´s F-12 (A549), or RPMI 1640 (all 
others) medium containing 10% heat-inactivated fetal bovine serum, 2 mmol 
glutamine, 100 IU/mL penicillin, and 100 µg/mL streptomycin. The cells 
were grown at 37oC in a humidified 5% CO2 atmosphere, split twice weekly, 
and harvested in log-phase for experimental use.  
 
 
3.2 EX VIVO 
3.2.1 Immunohistochemistry 
Formalin-fixed and paraffin-embedded tissue sections were used for 
detection of proteins. Tissue sections on glass slides were deparaffinized and 
rehydrated before microwave-citrate antigen retrieval. After blocking in 
bovine serum albumin (BSA) sections were incubated with primary antibody 
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at 4oC overnight. The next day, endogenous peroxidases were blocked using 
hydrogen peroxide, and then a SuperPicTure Polymer detection kit 
(Invitrogen, Paisley, UK) was used with the appropriate secondary antibody 
coupled to horseradish peroxidase (HRP) together with a 3,3´-
diaminobenzidine tetrahydrochloride substrate-chromogen system to 
visualize immunopositivity. All slides were counter-stained with hematoxylin 
and photographed in a light microscope. As a control for non-specific 
binding, matched isotype controls and antibody-specific blocking peptides 
were used. Tissue sections were also stained with hematoxylin and eosin 
(H&E) to show the tumor architecture. 
 
 
3.3 IN VITRO 
3.3.1 Immunoblotting 
Cells were harvested and pelleted and the proteins were extracted using RIPA 
buffer (Cell Signaling, Beverly, MA, USA) or M-PER buffer (Thermo Fisher 
Scientific, Göteborg, Sweden) supplemented with a cocktail of protease 
inhibitors (Roche Diagnostics, GmbH, Mannheim, Germany). For extraction 
of proteins from tissue, the samples were also sonicated. The protein 
concentration was determined using Bradford reagent (Bio-Rad, Sunbyberg, 
Sweden), and equal amounts were separated by SDS-PAGE and transferred 
to nylon or nitrocellulose membranes. The membranes were blocked in 5% 
BSA or dry milk before the primary antibody was added and were then 
incubated overnight at 4oC. After washing, the membranes were incubated 
with an appropriate secondary antibody conjugated with HRP. Pierce Super 
Signal (Pierce, Rockford, IL, USA) or ECL plus (GE Healthcare, Uppsala, 
Sweden) were used for detection. As a control for equal protein loading, all 
membranes were probed with an anti-β-actin antibody. 
 
For detection of phosphorylated proteins, all solutions added after 
trypsinization were cold and the samples were kept on ice. In addition, two 
phosphatase inhibitors, NaF and NaO2V4, were added to the RIPA buffer. 
 
 
3.3.2 Immunofluorescence 
Cells were grown on chamber slides, then washed and fixed in cold methanol 
or in 2% paraformaldehyde (PFA) followed by 70% methanol. After washing, 
slides were incubated overnight at 4oC with the primary antibody. Thereafter, 
a matched fluorescent secondary antibody was added and samples were 
analyzed in a fluorescence microscope. To show the cell nucleus, a mounting 
medium containing DAPI was used.  
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3.3.3 Fluorescence-activated cell sorting analysis (FACS) 
3.3.3.1 Analysis of BLT1 expression 
Cells were harvested, washed, and pelleted before a phycoerythrin (PE)-
conjugated BLT1 antibody or a PE-conjugated isotype matched control was 
added. After incubation, cells were washed twice and analyzed on the FL2 
channel on a FACS Calibur flow cytometer using Cell Quest software (BD 
Biosciences, San Jose, CA, USA). 
 
3.3.3.2 Measurement of the mitochondrial transmembrane potential 
After treatment in six-well plates, cells were incubated in 
tetramethylrhodamine ethyl ester (TMRE; Molecular Probes, OR, USA) for 
30 min prior to harvesting. Cells were harvested using the standard protocol 
with reagents containing 25 nM TMRE. The mitochondrial transmembrane 
potential was measured directly on the FL2 channel on a FACS Calibur flow 
cytometer using Cell Quest software (Becton-Dickinson).  
 
3.3.3.3 Analysis of cell DNA content 
After treatment in six-well plates, both detached and attached cells were 
harvested. The cells were fixed in 4% PFA at room temperature overnight, 
pelleted, and suspended in 95% ethanol. Thereafter samples were rehydrated 
in water prior to treatment with subtilisin Carlsberg solution (Sigma Aldrich, 
Stockholm, Sweden) and staining with DAPI-sulforhodamine solution. The 
samples were analyzed above 435 nM on a PAS II flow cytometer (Partec, 
Münster, Germany), and the multicycle program for cell cycle analysis 
(Phoenix Flow Systems, San Diego, CA) was used for histogram analysis.  
 
3.3.3.4 Analysis of TH-MYCN tumor single-cell suspensions 
Tumor tissue was mechanically digested in 0.1% phosphate buffered saline 
(PBS)/BSA using 100 µm cell strainers to get single-cell suspensions. The 
cells were washed and pelleted and the red blood cells were removed by 
incubation in a red blood cell lysis buffer (BD PharmLyse, BD Biosciences). 
After washing, 300.000 cells were incubated in a mouse-specific Fc receptor 
block (BD Biosciences) before fluorescently-labeled antibodies were added. 
For intracellular stainings, fixation and permeabilization was performed using 
cytofix/cytoperm (BD Biosciences) according to the manufacturer’s 
instructions. Cells were stained for 30 min, washed, and subsequently 
analyzed on an LSR II flow cytometer (BD Biosciences) using Flow Jo 
software (Treestar, Ashland, OR, USA). Prior to FACS analysis, an aqua dead 
cell marker (Invitrogen) was added to all samples. As a control for unspecific 
staining, isotype matched controls or fluorescence minus one was used. 
 
Ex vivo stimulation was performed in 12-well culture plates. Two million cells 
from tumor-single cell suspensions were incubated in RPMI medium 
   29 
containing 5 ng/mL phorbol 12-myristate 13-acetate (PMA) and 10 µM 
ionomycin. After one hour of incubation, GolgiStop (BD Biosciences) was 
added and the cells were further incubated for five hours. Thereafter, the cells 
were washed and subjected to antibody staining. 
 
 
3.3.4 Polymerase chain reaction (PCR) 
3.3.4.1 PCR 
Pups were earmarked and biopsied at 14 days of age. DNA was extracted 
from the tissue using the DNeasy Blood and Tissue kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. After extraction, DNA 
concentration and purity was determined using a nano-drop. Two PCR 
reactions were prepared for each DNA sample, one containing primers 
detecting the wild type allele, and one containing primers to detect the 
transgenic allele. The two PCR reactions were run in a GeneAmp PCR 
System 2400 (Applied Biosystems, Branchburg, NJ) and amplified using the 
same temperatures and cycle numbers. The PCR products were loaded in 
separate wells on a 1.5% agarose gel containing ethidium bromide or GelRed 
(Biotium, Hayward, CA, USA) and photographed under UV light. 
  
3.3.4.2 Reverse transcription-PCR 
Cells were harvested and pelleted and total RNA was extracted using Trizol 
reagent according to the manufacturer’s protocol (Life Technologies Inc., 
Carlsbad, CA, USA). For cDNA synthesis, 2 µg of RNA was reverse 
transcribed using a SuperScript Preamplification kit (Life Technologies). PCR 
was performed using different amounts of cDNA, and the PCR conditions 
were optimized for each primer pair. The PCR was performed in a PTC-200 
Peltier Thermal Cycler (MJ Research Inc., Waltham, MA, USA), and the final 
products were analyzed using agarose gel electrophoresis and photographed 
under UV light.  
 
3.3.4.3 Real-time reverse transcriptase-PCR 
Tumor tissue was collected and stored at -80oC. RNA was prepared from 30 
mg of tissue by mechanical dissociation using 100 µm cell strainers and an 
RNeasy mini-kit (Qiagen) according to the manufacturer’s instructions. 1 µg 
of total RNA was used for cDNA synthesis using a High Capacity RNA-to-
cDNA kit (Applied Biosystems). The PCRs were performed in MicroAmp 
optical 96-well plates, in a total volume of 25 µL of reaction mixture 
containing TaqMan Universal PCR Master Mix, TaqMan Gene Expression 
Assay (Applied Biosystems), and cDNA. 10 µL of cDNA was used for 
detection of the target gene, and 2 µL of cDNA was used for detection of the 
reference gene, hypoxanthine-guanine phosphoribosyl transferase (HPRT). 
All samples were run in triplicate and all experiments included a no template 
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control. PCR amplification was performed in an ABI PRISM 7500 sequence 
detection system (Applied Biosystems) and analyzed using 7500 software 
v2.0.4 (Applied Biosystems). From standard curves using a pooled cDNA 
sample, the efficiency of amplification for each primer was calculated. Each 
sample was corrected for the efficiency and the ∆CT value between the target 
gene, and HPRT was calculated as ∆CT=CTtarget-CTHPRT. 
 
 
3.3.5 Cell viability assays 
3.3.5.1 MTT assay  
To evaluate the impact of PGs and LTs on neuroblastoma cell viability, cells 
were seeded in 96-well plates and cultured overnight to attach. The next day, 
the medium was changed to RPMI medium without serum, and the cells 
were starved for 24 hours. Then the medium was changed to a fresh serum-
free RPMI medium containing LTD4, LTB4, or 16,16-dimethyl PGE2 
(dmPGE2), a stable PGE2 analogue. Plates were incubated for 24-96 hours 
and the medium was changed every second day. At final time points, cells 
were subjected to MTT assay, previously described by Mosmann (Mosmann, 
1983). The cell medium was removed and a serum-free medium containing 
0.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoleum bromide 
(MTT, Sigma Aldrich) was added. The plates were incubated for 2-3 hours at 
37oC, after which acidified isopropanol was added to dissolve the crystals. 
The plates were covered in aluminum foil and stored at 4oC overnight before 
absorbance was measured using a microplate reader at 595 nm. The viability 
ratio between control and treated cells was calculated.  
 
To investigate the effect of enzyme inhibitors and receptor antagonists on 
cell growth, neuroblastoma cells were incubated in the selected compounds 
or drug combinations, diluted in OptiMEM medium, as indicated. The cells 
were treated for 48 hours before they were subjected to MTT assay.  
 
3.3.5.2 WST-1 assay 
Prostate cancer cells were seeded in 96-well plates and cultured overnight. 
The next day, different concentrations of PGE2 were added just before the 
addition of 300 nM of adriamycin. PGE2 was added again after 12 hours of 
incubation. After 24 hours, cells were washed in PBS and 2-(4-Iodophenyl)-3-
(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST-1, Roche) was 
added. The plates were incubated at 37 oC for two hours and the absorbance 
was measured at 450 nM and 620 nM. The values are given as absorbance at 
450 nM (the formazan product) minus the absorbance at 620 nM (reference). 
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3.3.6 Clonogenic assay 
One hundred and fifty cells per well were seeded in 50 mm2 Cell+ Petri 
dishes. After 12 days of incubation, plates were rinsed with PBS, and the cells 
were fixed in PFA and stained with Giemsa (Gibco BRL, Sundbyberg, 
Sweden). Colonies with more than 75 cells were counted manually using a 
colony counter.  
 
 
3.3.7 Apoptosis assay 
Prostate cancer cells were seeded in 96-well plates and allowed to attach 
overnight. The following day, the medium was changed to a fresh medium 
containing 300 nM adriamycin. After 24 hours of incubation, 10% NP40 was 
added to lyse the cells. The amount of apoptotic cells was determined by 
measuring the amount of soluble caspase-cleaved fragments of cytokeratin 
18, using the M30 Apoptosense ELISA according to the manufacturer’s 
instructions (Peviva, Bromma, Sweden). 
 
 
3.3.8 Gene silencing 
3.3.8.1 Small interfering RNA (siRNA) 
Neuroblastoma cells were seeded in six-well plates and 15 cm Petri dishes 
and cultured to a 30-50% confluence. Cells were transfected with target or 
non-targeting siRNA (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
using Lipofectamin 2000 (Invitrogen) according to the manufacturer’s 
instructions. Seventy two hours after the initial transfection, cells were 
harvested and subjected to counting using tryphan blue exclusion, western 
blotting, or measurement of leukotriene production using enzyme immune 
assay (EIA), as described below. To measure the transfection efficiency, cells 
were transfected with a fluorescein-labeled non-targeting siRNA. These cells 
were harvested, washed, and analyzed on the FL1 channel on a FACS Calibur 
flow cytometer using Cell Quest software (BD Biosciences). 
 
3.3.8.2 Small hairpin RNA (shRNA) 
Prostate and lung cancer cells were seeded in six-well plates. Cells were 
transfected with vector plasmid (MISSION pLKO.1-puro, Sigma Aldrich) 
encoding mPGES-1 specific shRNA or non-targeting shRNA, using 
Lipofectamin 2000 (Invitrogen) according to the manufacturer’s protocol. By 
culturing the cells in 8 µg/mL puromycin, stably transfected clones could be 
isolated. As a control for successful downregulation, expression of mPGES-1 
was evaluated using western blotting and real-time RT-PCR, and the 
mPGES-1 enzyme activity was measured as described below. 
 
 
 32 
3.3.9 Intracellular calcium mobilization 
Cells were seeded on cover slips in Petri dishes and cultured overnight. The 
medium was changed to a Krebs-Ringer solution containing 5 µM of the 
calcium fluorescent dye Fluo-4/AM (Invitrogen), and the cells were 
incubated for 30 min at 37ºC. Thereafter, cells were washed with Krebs-
Ringer solution and examined with a confocal laser scanning microscope 
(Zeiss LSM 510 META). A 5-min baseline, with or without 2 mM of ethylene 
glycol tetraacetic acid (EGTA), was determined for each sample before 1 µM 
of dmPGE2 was added. 
 
 
3.3.10 Intracellular concentration of cAMP 
Cells were seeded in Petri dishes and cultured for 48 hours. The medium was 
changed to a serum-free RPMI medium and the plates were incubated 
overnight before, the indicated compounds were added. After treatment, cells 
were rinsed with PBS and lysed in 0.1 M HCl at room temperature. The 
plates were scraped, the lysate was collected and centrifuged and the 
supernatant was used for intracellular cAMP determination using EIA, 
according to the manufacturer’s protocol (Cayman Chemical, Ann Arbor, MI, 
USA).  
 
 
3.3.11 Lipid measurements  
3.3.11.1 Liquid chromatography – tandem mass spectrometry  
(LC-MS/MS)  
Cells were cultured in clear OptiMEM medium with or without 40 µM of 
arachidonic acid and 10 ng/mL of IL-1β for 12-48 hours. At the end of 
incubation, cells were harvested, washed in PBS, and counted using tryphan 
blue exclusion. 8-20 million cells were suspended in PBS supplemented with 
protease inhibitors, sonicated on ice, and further incubated in 80 µM of 
arachidonic acid for 30 min at 37°C. Awaiting further analysis samples were 
stored at -80°C. To extract the lipids from the cell homogenates, a liquid-
liquid extraction method described previously (Kempen et al., 2001) was used. 
Briefly, internal standard PGE2-d4 was added to each sample before an 
addition of 1:1 v/v hexane:ethyl acetate. Samples, standards, and controls 
were mixed and centrifuged, and the upper organic phase was collected, 
whereas the lower water phase was extracted twice more. Stock solutions of 
PGE2 and PGD2 were prepared in methanol and further diluted in PBS for 
preparation of standards. The chromatic system consisted of Waters Acquity 
UPLC system (Waters Corp., Milford, MA, USA) and liquid chromatography 
was performed on a 2.1 x 100 mm Waters Acquity HSS T3 (C18) UPLC 
column maintained at 50°C with a programmed gradient from solvent A 
(methanol/water/ammonium acetate of 10/90/2 mM, v/v/concentration) to 
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B (methanol/water/ammonium acetate 90/10/2 mM, v/v/concentration) at 
0.4 ml/min to resolve PGE2 from PGD2.  
Mass spectrometry was performed using a Waters Quattro Premier XE 
tandem quadrupole mass spectrometer (Waters Corp). The system was 
controlled by MassLynx version 4.1 and the ionization was achieved using 
electrospray in a negative ionization mode. The injection volume was 15 µl 
and the injection interval was 7 min. LC-MS/MS was performed with an 
autosampler temperature of 5°C, a desolvation gas temperature of 340°C, a 
source temperature of 120°C, a desolvation gas flow of 900 L/h, a cone gas 
flow of 40 L/h, a collision gas pressure of 3.5 x 10-3 mBar (argon), and ion 
energies of 0.9 V for both quadrupoles. Quantitative analysis was performed 
in the multiple reaction monitoring (MRM) mode with the following 
transitions: m/z 351→315 (quantification ion), 351→271 (qualifier ion), and 
351→315 (qualifier ion). For the internal standards, MRM transitions m/z 
355→319 and 355→275 were used. The dwell time was set to 20 ms for each 
transition. The method demonstrated a good linearity and reproducibility 
with a correlation coefficient (r2) of >0.99 and a coefficient of variation of 
<10%. 
 
3.3.11.2 High-performance liquid chromatography (HPLC)  
The enzymatic activity of mPGES-1 was determined using a method 
previously described (Thoren and Jakobsson, 2000). Harvested and pelleted 
cells were resuspended in a 0.1 M potassium phosphate buffer, supplemented 
with a cocktail of protease inhibitors, and sonicated three times on ice. 
Homogenates were subjected to differential centrifugation at 10.000 x g for 
15 min and at 100.000 x g for two hours, at 4°C. Microsomal fractions were 
resuspended in a potassium buffer containing 10% v/v glycerol, and an 
aliquot of 25 µg protein was removed and incubated with 10 µM of PGH2 for 
10 min on ice. PGH2 was produced by stirring 1 mM of arachidonic acid in a 
suspension of the microsomal fraction of whole homogenates of sheep 
vesicular glands, together with L-tryptophan. After 2 min, PGH2 was 
extracted with diethyl ether and purified by normal-phase HPLC. The solvent 
system consisted of 2-propanol-hexane-acetic acid (2.5/97.5/0.002; v/v/v) 
and afforded a purity of >95%. PGH2 was dissolved in dry aceton and stored 
at -80 °C for further use. During the experiment, PGH2 was kept on dry ice. 
The reaction was stopped by addition of a iron (II) chloride solution 
supplemented with 11-β-PGE2 as an internal standard to estimate the 
extraction efficiency. The samples were further subjected to solid-phase 
extraction using Oasis HLB columns (Waters Corp). The samples were 
separated by reversed-phase HPLC on a Waters 2790 HPLC system 
equipped with a NovaPak C18 column (3.9 mm x 150 mm x 4 µm) and 
eluated with water/acetonitrile/formic acid (62/38/0.0025; v/v/v) at a flow 
rate of 0.3 mL/min. The products were monitored using UV light on a 
Waters 996 diode array detector at 195 nm. Standards of different 
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concentrations were processed in the same way, and the product was 
quantified by integration of the peak areas. 
 
3.3.11.3 Enzyme immunoassay (EIA)  
For measurement of LT production, tumor tissue and cells were suspended 
in Ca2+- and Mg2+-free PBS supplemented with a cocktail of protease 
inhibitors (Roche). Samples were homogenized and sonicated three times on 
ice prior to the addition of 2 mM ATP, 2 mM Ca2+, and 80 µM of 
arachidonic acid. After incubation for 10 min at 37°C, the reaction was 
quenched with an equal volume of methanol and acidified to pH 3-4 for 
detection of LTB4 or to pH 5-6 for detection of CysLTs. Thereafter, samples 
were purified and concentrated by solid-phase extraction (Supelclean LC-18, 
Sigma Aldrich), eluted in methanol, and dried under nitrogen. The residue 
was reconstituted in an EIA buffer and subjected to EIA for determination 
of the concentration of LTB4 and CysLTs according to the manufacturer’s 
protocol (Cayman Chemicals).  
 
 
3.4 IN VIVO 
3.4.1 Xenograft mouse model 
Female athymic mice NMRI nu/nu (Taconic Laboratories, Ejby, Denmark), 
four to eight weeks old, were used for in vivo xenograft experiments. Mice 
were housed and maintained under special pathogen-free conditions with 
access to sterile water and food ad libitum. DU145 and A549 xenografts were 
established by injection of 2 x106 or 5 x106 cells, respectively, subcutaneously 
in both flanks under general anaesthesia (2-4% Isofluran). For each cell line, 
wild type, mPGES-1 knocked down and non-targeting shRNA control cells 
were injected into different mice. Tumor development and growth was 
monitored every day. The size of the tumor was measured with a digital 
calliper, and the volume was calculated by the formula width2 x length x 0.44. 
A tumor was considered to be established when it had grown to a volume of 
0.2 mL and the mice were followed for tumor development for up to 72 days 
after the tumor cell injection. The mice were euthanized in carbon dioxide 
and the tumor was excised, weighted, divided, and snap frozen in liquid 
nitrogen for storage at -80°C, or fixed in 4% PFA and stored at 4°C. All 
animal experiments were approved by the regional ethics committee and in 
accordance with the Swedish national regulations, including the Animal 
Protection law (SFS1988:534), the Animal Protection regulation 
(SFS1988:539), and the Regulations for the Swedish National Board for 
Laboratory Animals (SFS1988:541). 
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3.4.2 The TH-MYCN transgenic model  
Transgenic TH-MYCN mice spontaneously develop neuroblastoma due to a 
targeted expression of the MYCN oncogene to migrating cells of the neural 
crest (Weiss et al., 1997). The animals develop predominantly palpable 
abdominal tumors, but thoracic tumors may also occur. In our hands, 100% 
of the homozygous develop tumors within seven weeks of age and 50% of 
the hemizygous mice develop tumors within 6-19 weeks (Rasmuson et al., 
unpublished). The animals were obtained from the Mouse Model of Human 
Cancer Consortium Repository as an N16 backcross to the 129X1/SvJ 
background, and have since been kept as a continuous inbreeding. Breeders 
were kept in harems, and pups were earmarked and biopsied at two weeks of 
age. The animals were housed at a maximum of six per cage in an enriched 
environment with access to food and water ad libitum. At 4.5 weeks of age, 
homozygous mice were randomized to receive either no treatment or a daily 
treatment with 10 mg/kg ASA (Sigma Aldrich) by oral gavage for 10 
consecutive days. All animals underwent abdominal palpations two to three 
times weekly to monitor tumor development. Upon palpable tumor, the 
animals were monitored closely and euthanized upon signs of discomfort, 
tumor-related problems, or heavy tumor burden. At sacrifice, the animals 
were euthanized using carbon dioxide and cardiac blood was drawn. The 
blood was put into EDTA tubes and centrifuged at 3000 rpm for 10 min, and 
the cell component was collected used for FACS analysis. The tumor was 
excised and put in PBS on ice, weighted and divided for: FACS analysis, 
fixation in 4% PFA or storage at -80°C for further analysis. All animal 
experiments were approved by the regional ethics committee and in 
accordance with the Swedish national regulations.   
 
 
3.5 STATISTICAL ANALYSIS 
For the in vitro studies, parametric tests were used to determine statistically 
significant differences. Comparisons between two independent groups were 
analyzed by t-test, the data was log transformed when indicated, and several 
independent groups were analyzed by two-way ANOVA. One sample t-test 
was performed to test if the mean of a single sample was significantly 
different from the control. For the in vivo studies, non-parametric tests were 
used. The Mann-Whitney U-test was performed for the comparison between 
two independent groups, and the Kruskall-Wallis test, followed by Dunn’s 
multiple comparison test, was used for the comparison between several 
independent groups. The Spearman test was performed to determine if a 
correlation existed between two paired observations. All tests were two-sided, 
and p<0.05 was considered significant. 
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4 RESULTS AND DISCUSSION 
 
4.1 PGE2 SIGNALING IN CANCER 
4.1.1 PGE2 signaling in neuroblastoma (Paper I) 
Our group has previously shown that COX-2 is overexpressed in 
neuroblastoma (Johnsen et al., 2004) and that therapeutic treatment of 
neuroblastoma xenografts with diclofenac, a dual COX-1 and COX-2 
inhibitor, or celecoxib, a specific COX-2 inhibitor, induces apoptosis and 
reduces tumor growth (Johnsen et al., 2004). To further investigate why 
COX-2 is important for neuroblastoma cell survival, we studied the role of 
PGE2 and its receptors. 
 
4.1.1.1 Production of PGE2 and expression of PGE2 receptors 
To determine if neuroblastoma cells produce PGE2, SK-N-SH, and SK-N-
BE(2), cells were incubated with arachidonic acid, the substrate for PG 
biosynthesis, alone or in combination with the inflammatory mediator IL-1β, 
and PGE2 production was measured using LC-MS/MS. The MYCN-
amplified, drug-resistant cell line SK-N-BE(2) produced PGE2 under normal 
culture conditions, whereas SK-N-SH cells did not produce detectable levels 
of PGE2. When the cells were cultured with arachidonic acid, both cell lines 
produced PGE2, and stimulation with IL-1β further increased the production. 
Hence, these results are consistent with earlier findings about the inducible 
nature of COX-2 and mPGES-1 (Samuelsson et al., 2007). We also 
investigated if PGE2 could rescue neuroblastoma cells from apoptosis 
induced by COX-2 inhibition. Treatment of SK-N-BE(2) cells with 35 µM 
celecoxib resulted in a 70% reduction in cell viability. A concomitant addition 
of PGE2 rescued the cells from celecoxib-induced cytotoxicity, and the cell 
viability after 48 hours of incubation was 86% of the control. To further 
determine whether neuroblastoma cells expressed any of the PGE2 receptors, 
EP1-EP4, 28 neuroblastoma primary tumors were evaluated using 
immunohistochemistry, and a panel of seven neuroblastoma cell lines was 
analyzed with RT-PCR, western blotting and immunofluorescence. 
Expression of all four receptors was detected in all primary tumors and cell 
lines investigated, independent of biological characteristics and clinical stage. 
In addition, some expression was also detected in the adjacent stroma. The 
immunofluorescence staining revealed that all four receptors are expressed at 
the cell membrane, and that EP1 and EP4 are also expressed in the nuclear 
compartment. 
 
The existence and differential expression of EP1-EP4 enable a wide range of 
PGE2 actions. Our results here agree with our previous study on the 
childhood brain tumor medulloblastoma, which also shows expression of all 
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four receptor subtypes (Baryawno et al., 2008), and with the many studies on 
adult epithelial cancers that show a complex EP receptor profile that often 
has several receptors expressed, but at a different level compared to normal 
tissue (Lee et al., 2005; Miyata et al., 2006; Gustafsson et al., 2007a). Very little 
is known about the precise role of each EP receptor in malignant behavior. 
Studies using mice deficient in each of the EP1-EP4 receptors have 
implicated all four receptors in different stages of carcinogenesis. However, 
the results are difficult to interpret because they vary depending on the model 
used (Fulton et al., 2006). 
 
The production of PGE2 takes place at the endoplasmic reticulum and at the 
nuclear envelope (Morita et al., 1995). The presence of nuclear EP receptors 
indicates that PGE2 can act intracellularly, and can potentially mediate distinct 
functions from receptors expressed at the cell membrane, thereby possibly 
affecting gene transcription (Zhu et al., 2006; Reader et al., 2011). Support for 
the idea of a different function for nuclear EP receptors comes from a breast 
cancer study that showed that a nuclear expression of EP1, though not 
cytoplasmic, is associated with a significantly better prognosis (Ma et al., 
2010). The study proposes that EP1 may act to suppress metastatic spread.  
 
4.1.1.2 PGE2 and neuroblastoma cell survival and proliferation  
Because our results demonstrated that neuroblastoma cells express all four 
receptor subtypes and produce PGE2, we decided to focus this study on the 
response of neuroblastoma cells to PGE2. SK-N-SH and SK-N-BE(2) cells 
were serum-starved overnight before being incubated with PGE2 at different 
concentrations and durations. A significant dose-, time-, and cell line-
dependent increase in cell viability and proliferation was observed. To 
elucidate the mechanisms behind the observed effect on cell viability, and to 
test the functionality of the receptors, we investigated the activation of 
second messengers and effectors by PGE2. We performed confocal laser 
scanning microscopy, using the calcium fluorescent dye Fluo-4/AM to detect 
changes in the intracellular calcium concentration, since activation of EP1 
results in an increased calcium level. PGE2 induced a rapid increase in the 
concentration of cytoplasmic calcium. EGTA, a calcium chelator, did not 
alter the response, which shows that calcium is released from intracellular 
stores. Because EP2, EP3, and EP4 act through adenylate cyclase and cAMP, 
we also investigated the effect of PGE2 on cAMP. A net response of 
increased cAMP was observed in neuroblastoma cells after 20 min of PGE2 
incubation. NF-449, a Gαs inhibitor, prevented cAMP accumulation. We also 
performed western blotting to investigate the effect of PGE2 on the 
phosphorylation status of Akt, which is a key protein involved in cell 
proliferation and the survival of cancer cells and neuroblastoma. Incubation 
with PGE2 increased the phosphorylation, thus activating Akt signaling in 
both neuroblastoma cell lines investigated. 
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In agreement with our results, one other study has shown that PGE2 
increases the intracellular calcium concentration in cholangiocarcinoma cells 
(Zhang et al., 2007). Several studies using epithelial cancer cell lines have 
confirmed functional EP2 and EP4 receptors (Castellone et al., 2005) and a 
subsequent generation of cAMP in response to PGE2 (Chang et al., 2005; 
Subbaramaiah et al., 2008). cAMP has been shown to increase proliferation in 
some cancer cells, whereas in other cancer types cAMP induces 
differentiation (Borland et al., 2009; Naviglio et al., 2009). Neuroblastoma cells 
have been shown to contain very low levels of cAMP, and incubation with 
dibutyryl cAMP, a cAMP analog, induces differentiation in vitro (Prasad et al., 
2003). In addition, retinoic acid-differentiated neuroblastoma cells respond to 
PGE2 by an elevated production of cAMP compared to control cells (Prasad 
et al., 2003). To my knowledge, only one other study has investigated the role 
of PGE2 receptors in neuroblastoma, and it revealed that incubation with 
butaprost, an EP2 receptor agonist, or overexpression of the EP2 receptor 
with a concomitant increase in cAMP, reduced cell growth and induced 
apoptosis (Sugino et al., 2007). Taken together, our results show that 
neuroblastoma cells respond to PGE2 by the activation of several EP 
receptors. However, PGE2 receptor signaling is more complex than the effect 
on calcium and cAMP. For instance, the receptors often couple to more than 
one type of G-protein, the βγ subunits can activate downstream effectors and 
G-protein independent signaling has been reported (Hirata and Narumiya, 
2011). 
 
Numerous studies have shown that PGE2 increases the proliferation of 
cancer cells of epithelial origin (Wang and Dubois, 2010). Both this current 
study and our previous study on medulloblastoma (Baryawno et al., 2008) 
show that PGE2 also increases the proliferation of cancer cells derived from 
pediatric tumors of neural origin. PGE2 has been shown to activate many 
different pathways in epithelial cancers that promote proliferation and 
survival and inhibit apoptosis, such as Akt, Erk, Wnt, EGFR, and the 
downregulation of Bcl-2 (Wang and Dubois, 2010). In neuroblastoma, the 
activation of Akt has been demonstrated to correlate with a poor prognosis 
(Opel et al., 2007), and the inhibition of Akt signaling represents a promising 
target for neuroblastoma therapy (Sartelet et al., 2008). Akt is an important 
regulator of various cellular processes and stimulates protein synthesis, cell 
growth, and proliferation while inhibiting apoptosis (Sartelet et al., 2008). 
Here, we found that PGE2 activates Akt in neuroblastoma. 
 
PGE2 released from neuroblastoma cells could also influence the behavior of 
immune cells and other stromal cells within the tumor to help subvert an 
anti-tumor response and promote the establishment of an 
immunosuppressive tumor microenvironment. Experimental data indicates 
that metastatic neuroblastoma cells present in the bone marrow produce 
PGE2 (Ara et al., 2009) and galectin-3 (Song et al., 2009). This stimulates bone 
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marrow stromal cells to produce IL-6, which in turn activates ostoclasts and 
thereby facilitates bone invasion (Sohara et al., 2005). In addition, IL-6 
released by the bone marrow stromal cells stimulates neuroblastoma cell 
proliferation and survival (Ara et al., 2009; Song et al., 2009). 
 
An alternative approach for targeting COX-2 activity to inhibit PGE2 
signaling is to block the binding of PGE2 to its receptors. To determine if any 
of the receptors are crucial for neuroblastoma cell survival, we treated 
neuroblastoma cells with a panel of EP receptor antagonists at different 
concentrations for 48 hours. The most effective drugs in reducing cell 
viability were antagonists that inhibited signaling through the EP1, EP3, and 
EP4 receptors. Because of a lack of specific antagonists, the EP2 receptor 
could not be specifically inhibited. These results indicate that more than one 
receptor is important for neuroblastoma cell viability, though the results are 
also dependent on differences in affinity and the specificity of the antagonist 
for the respective receptor. 
 
Together, these data show that PGE2 acts as an autocrine and/or paracrine 
proliferation and survival factor for neuroblastoma, and suggests that the 
specific inhibition of PGE2 signaling may be effective in neuroblastoma 
treatment. 
 
 
4.1.2 mPGES-1 in prostate and lung cancer (Paper II) 
Unlike with the other PGE synthases and COX-1, the expression of both 
mPGES-1 and COX-2 can be induced by inflammatory stimuli, and both are 
inhibited by treatment with glucocorticoids. mPGES-1 has been suggested to 
predominantly couple with COX-2 (Jakobsson et al., 1999; Thoren and 
Jakobsson, 2000); therefore, inhibition of this enzyme may represent a more 
specific target for preventing both PGE2 signaling in cancer and the side 
effects of COX-2 inhibitors. 
 
4.1.2.1 Expression of mPGES-1 
To investigate if mPGES-1 is expressed in prostate cancer, tumor tissues 
were analyzed with western blotting, and three cell lines were analyzed using 
western blotting and immunofluorescence. We observed a differential 
expression of mPGES-1 in prostate cancer, with a tendency towards a higher 
expression in malignant tumors. Two out of three prostate cancer cell lines, 
DU145 and PC3, constitutively expressed detectable levels of mPGES-1 in a 
noninducible manner, and the expression level correlated well with the 
production of PGE2. However, the expression of mPGES-1 can also be 
inducible in cancer cells, as exemplified by the non-small lung cancer cell line, 
A549. 
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An intermediate expression of mPGES-1 has been detected in normal 
prostate tissue (Jakobsson et al., 1999). In fact, PGs are named after the 
prostate gland because they were first discovered in seminal fluid and were 
therefore thought to be produced in the prostate gland, though, PGs were 
later found to be produced in seminal vesicles. The expression of mPGES-1 
has also been detected in various other epithelial cancers, such as those of the 
colon, pancreas, cervix, and stomach; and in non-small cell lung cancer; but 
also in brain tumors such as glioma (Nakanishi et al., 2010) and 
medulloblastoma (Baryawno et al., 2008). 
 
The expression of mPGES-1 and COX-2 can be induced by inflammatory 
stimuli such as IL-1β, TNFα, and lipopolysaccharides, with a tandem 
induction of mPGES-1 and COX-2 being most often observed (Samuelsson 
et al., 2007). However, cancer tissues frequently express mPGES-1 and COX-
2 differentially, even in individual tumors (Samuelsson et al., 2007). Here, we 
show that the prostate cancer cell line, DU145, constitutively expressed high 
levels of mPGES-1. However, immunofluorescence stainings revealed a 
translocation of mPGES-1 to the nucleus upon IL-1β stimulation, which 
could promote PGE2 production. In contrast, COX-2 is expressed at a low 
level in these cells, and the expression can be induced by IL-1β stimulation. 
Similarly, another study has shown the differential constitutive expression of 
mPGES-1 and an inducible expression of COX-2 in gastric cancer cell lines 
(van Rees et al., 2003). On the other hand, we show here, and others have 
shown previously, that stimulation of the A549 lung cancer cell line, with IL-
1β (Jakobsson et al., 1999), TNFα (Yoshimatsu et al., 2001), or PMA (van 
Rees et al., 2003) increases the expression of both mPGES-1 and COX-2. 
However, two of the previous studies documented that the time course and 
magnitude of induction of mPGES-1 and COX-2 after incubation with 
TNFα and PMA were markedly different (Yoshimatsu et al., 2001; van Rees et 
al., 2003). In contrast, TNFα did not have any effect on mPGES-1 and COX-
2 in non-transformed control cells, but in these cells an overexpression of the 
oncogene Ras could enhance the transcription of mPGES-1 (Yoshimatsu et 
al., 2001). In summary, these results show that the expression of mPGES-1 
and COX-2 is controlled by different pathways in cancer cells, and indicate 
that the regulation is not even similar in all cancer cells.  
 
PGE2 can also be produced by transcellular metabolism, and A549 cells can 
take up PGH2 that is released from human umbilical vein endothelial cells 
and further convert it to PGE2 (Salvado et al., 2009). Consequently, a 
concomitant expression of mPGES-1 and COX-2 may not be necessary for 
cancer cells to produce PGE2.  
 
4.1.2.2 Phenotypic changes due to mPGES-1 knockdown  
No clinical trials with mPGES-1 inhibitors have yet been reported. The 
development of specific mPGES-1 inhibitors has been greatly hampered by 
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interspecies differences that complicate animal testing and preclinical studies. 
Potent inhibitors of human mPGES-1 either partially or totally lose their 
inhibitory effect against the rodent form. Three amino acid residues in human 
mPGES-1, thr-131, leu-135 and ala-138, correspond to the rat mPGES-1 
residues val-131, phe-135 and phe-138, which line the entrance of the active 
site. These amino acid residues account for most of this effect (Smith et al., 
2011). 
 
To study the role of mPGES-1 in tumorigenesis, we established stable 
DU145 and A549 mPGES-1 knockdown clones by using shRNA. The 
downregulation of mPGES-1 expression was confirmed by real-time PCR 
and western blotting, and the production of PGE2 was reduced by 85-90%. 
mPGES-1 knockdown clones had a significantly smaller clonogenic capacity 
than control cells that were transfected with non-targeting shRNA. To 
investigate the tumorigenic potential of these cells in vivo, athymic mice were 
injected with either DU145 or A549 wild type cells, non-targeting shRNA 
control cells, or mPGES-1 knockdown cells, respectively. The time to tumor 
take (0.2 mL) was monitored for all six groups after tumor cell injection. A 
significant delay in tumor development was observed for mPGES-1 
knockdown xenografts, and only nine of 20 injections of DU145 mPGES-1 
knockdown cells and five out of 20 injections of A549 mPGES-1 
knockdown cells developed into tumors. Tumors from mPGES-1 
knockdown xenografts also appeared less proliferative and more necrotic 
compared to control. An ex vivo analysis of mPGES-1 revealed an expression 
of mPGES-1 in all tumors independent of what cells had been injected, 
which could be explained by the expression of mPGES-1 in other tumor 
stromal cells (Kamei et al., 2009; Sasaki et al., 2011). 
 
Thus, the production of PGE2 by the cancer cells is important for tumor 
development and growth, although the effect seems to be independent of the 
expression pattern of mPGES-1. Other studies have shown that chemical 
carcinogen-induced colon and intestinal tumorigenesis is suppressed in 
mPGES-1 knockout mice (Nakanishi et al., 2008; Nakanishi et al., 2011; Sasaki 
et al., 2011) and that these mice show a reduced metastatic bone cancer 
growth (Isono et al., 2011). However, one study displays the opposite effect, 
an accelerated intestinal tumorigenesis when mPGES-1 is genetically deleted 
(Elander et al., 2008). The authors propose that this could be explained by a 
metabolic shunt towards the production of other pro-tumorigenic PGs and 
TXA2 (Elander et al., 2008). In addition, two studies have shown that host-
associated mPGES-1 expression also significantly contributes to tumor 
growth, angiogenesis and metastatic spread (Kamei et al., 2009; Sasaki et al., 
2011). 
 
Adriamycin, or doxorubicin, is a chemotherapeutic drug that intercalates 
DNA and inhibits macromolecular biosynthesis. DU145 mPGES-1 
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knockdown cells were significantly more sensitive to adriamycin-induced 
apoptosis than control cells, and the addition of PGE2 to the cell cultures 
could rescue the cells from cell death. However, the same effect was not 
observed for A549 knockdown cells. One possible explanation for this 
observed difference is the high anti-oxidative capacity of A549 cells, which 
protects them from genotoxic stress (Radmark and Samuelsson, 2010). No 
other study has yet investigated the effect of mPGES-1 inhibition on the 
cytotoxic effect of chemotherapeutic drugs, but studies have shown that 
celecoxib and NSAIDs can act in synergy with adriamycin (Duffy et al., 1998; 
Ponthan et al., 2007; Roy et al., 2010). 
 
Together, these results confirm that the inhibition of mPGES-1 may 
represent an alternative, more specific therapeutic approach for NSAIDs and 
COX-2 inhibitors in cancer therapy.  
 
 
4.2 5-LO AND THE LEUKOTRIENES IN NEUROBLASTOMA 
(PAPER III) 
As with the COX enzymes, the main substrate for 5-LO and LT biosynthesis 
is arachidonic acid. Since neuroblastoma cells are enriched in arachidonic acid 
(Reynolds et al., 2001), and because LTs are pro-inflammatory mediators, we 
decided to investigate if the 5-LO pathway is present in neuroblastoma, and if 
so, clarify the role of this pathway in neuroblastoma cell survival and 
proliferation.  
 
 
4.2.1 Expression of the 5-LO pathway and production of 
leukotrienes  
We used immunohistochemistry to analyze 27 neuroblastoma tissue samples, 
three ganglioneuromas, and three nonmalignant adrenals from children for 
the expression of enzymes and receptors in the 5-LO pathway. Some 
neuroblastomas spontaneously differentiate or mature into a benign tumor 
called a ganglioneuroma. The characteristic of these tumors is that they are 
stroma rich, with differentiating neuroblasts and/or mature or maturing 
ganglion cells (Brodeur, 2000). The staining revealed that neuroblastoma 
tumor cells and tumor-derived ganglion cells of ganglioneuromas express 5-
LO, FLAP, LTA4H, and LTC4S, as well as the LTB4 receptor BLT1 and the 
CysLT receptors CysLT1 and CysLT2. Nonmalignant adrenals demonstrated 
an expression of 5-LO and FLAP in the cortex but not in the medulla, where 
neuroblastomas arise. Moreover, nonmalignant adrenals expressed LTA4H, 
LTC4S, and the LT receptors both in the cortex and medulla. Using RT-PCR, 
western blotting and flow cytometry, we could detect mRNA and protein 
that corresponded to each of the enzymes and receptors in a panel of seven 
   43 
neuroblastoma cell lines. Hence, neuroblastoma cells express all enzymes 
required for the synthesis of both LTB4 and LTC4. To determine if 
neuroblastoma cells could produce LTs, we measured de novo production 
from primary neuroblastoma tumors and cell lines. Indeed, both LTB4 and 
CysLTs could be detected, which shows that neuroblastoma cells 
endogenously produce LTs. In tumor tissue, however, infiltrating leukocytes 
could also contribute to the total production. 
 
The role of the 5-LO pathway and LTs in the adrenal gland is not fully clear, 
though it has been suggested that they are involved in hormone production 
by adrenal cortical cells (Hirai et al., 1985; Schroder et al., 2005). The 
expression of 5-LO has previously been shown in cells of neuronal origin, 
and 5-LO has been detected in neural stem cells (Wada et al., 2006) and 
immature cortical neurons, although to a lesser extent in mature cultures (Uz 
et al., 2001). Functional studies suggest that 5-LO and LTB4 are important for 
the proliferation and differentiation of these cells (Uz et al., 2001; Wada et al., 
2006). 5-LO is also expressed in various brain tumors (Boado et al., 1992; 
Ishii et al., 2009; Lim et al., 2010), and an increased production of LTs is 
correlated with a more advanced disease (Simmet et al., 1990). Furthermore, 
5-LO is also expressed in a variety of epithelial cancers (Steinhilber et al., 
2010). 
 
Neuroblastoma expressed LTA4H and produced LTB4. Only one other study 
has investigated and demonstrated an expression of LTA4H in cancer cells 
and infiltrating inflammatory cells of esophageal adenocarcinomas, and the 
study showed that treatment with bestatin, a LTA4H inhibitor, reduced LTB4 
production and tumor incidence in vivo (Chen et al., 2003). Increased levels of 
LTB4 have also been detected in oral (el-Hakim et al., 1990) and prostate 
(Larre et al., 2008) cancer tissues. Here, we show that neuroblastoma cells 
endogenously produce LTB4 and express the BLT1 receptor, thereby 
suggesting that LTs could affect the behavior of neuroblastoma cells. An 
upregulated expression of BLT1 has been shown in pancreatic (Hennig et al., 
2002), colon (Ihara et al., 2007), and ovarian cancer (Rocconi et al., 2008), 
while no increased expression was detected in bladder cancer (Kim et al., 
2010). At the time of this study, no commercial antibodies were available to 
study the expression of BLT2, although it has now been shown that BLT2 is 
overexpressed not only in pancreatic (Hennig et al., 2008) and breast cancer 
(Choi et al., 2010), but also in ovarian (Rocconi et al., 2008) and bladder 
cancer (Kim et al., 2010), in which the expression of BLT2 significantly 
correlated with an advanced disease stage and poor prognosis. Signaling 
through BLT2 has been shown to promote tumor cell proliferation (Hennig 
et al., 2008), survival (Choi et al., 2010), invasion, and metastasis (Kim et al., 
2010).  
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In addition, neuroblastoma cells express LTC4S, produce CysLTs and express 
the receptors CysLT1 and CysLT2. According to the literature, no other 
study has investigated the expression of LTC4S in solid tumors; however, an 
elevated concentration of CysLTs has previously been detected in brain 
tumors (Simmet et al., 1990). An increased expression of the CysLT1 receptor 
has also been found in tissues from urological (Matsuyama et al., 2009), colon 
(Ohd et al., 2003), breast (Magnusson et al., 2011), and brain (Zhang et al., 
2004) cancers. In colon cancer, CysLT1 has been shown to be expressed both 
in the cellular and nuclear membrane (Nielsen et al., 2005). Interestingly, the 
activation of nuclear CysLT1 receptors triggered a calcium response, induced 
the phosphorylation of Erk1/2, and stimulated cell proliferation (Nielsen et 
al., 2005), which indicates a distinct nuclear CysLT1 signaling. By contrast, 
signaling through the CysLT2 receptor may be involved in differentiation 
(Magnusson et al., 2007) and decreased cell growth and migration 
(Magnusson et al., 2011). A high expression of CysLT1, together with a low 
expression of CysLT2, correlates with a worse prognosis for colon 
(Magnusson et al., 2010) and breast (Magnusson et al., 2011) cancer patients. 
Moreover, no expression of CysLT2 was detected in brain tumors, although a 
high expression was detected in neuronal and glial cells in the surrounding 
stroma (Hu et al., 2005). 
 
 
4.2.2 5-LO and the leukotrienes in neuroblastoma cell survival 
and proliferation 
To investigate the effect of LTs on neuroblastoma cell viability, we serum-
starved cells overnight and added LTB4 or LTD4 at different concentrations 
and durations. A significant time- and cell line-dependent increase in cell 
viability was observed for both SK-N-AS and SK-N-BE(2) cells. A panel of 
neuroblastoma cell lines was also treated with 13 different LO pathway 
inhibitors and LT receptor antagonists at different concentrations for 48 
hours. The most effective compounds to decrease neuroblastoma cell 
survival were AA-861, a 5-LO inhibitor; MK-886, a FLAP inhibitor; and 
montelukast, a CysLT1 receptor antagonist. The drug concentration that was 
needed to inhibit 50% of the cell viability ranged from 2-14 µM. These results 
suggest that LTs are important for neuroblastoma cell survival and 
proliferation. To investigate the mechanisms behind the decreased cell 
survival, we performed cell cycle distribution analysis using DAPI staining, 
and we observed a sub-G1 peak, an indicator of apoptosis, in SK-N-SH cells 
treated with AA-861, MK-886, or montelukast. For SK-N-BE(2) cells, we 
observed an increase in G1, which indicates cell cycle arrest after treatment 
with AA-861 or MK-886 and a sub-G1 peak after treatment with 
montelukast. To further determine the effect of AA-861 and MK-886, we 
stained cells with annexin V, which binds to phosphatidylserine on the cell 
surface of early apoptotic cells. Treatment with AA-861 or MK-886 resulted 
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in a positive annexin V staining. We also investigated the mitochondrial 
membrane potential using TMRE, since depolarization of the mitochondrial 
membrane is one of the first steps of apoptosis. All three compounds 
induced depolarization of the mitochondrial membrane in the two 
neuroblastoma cell lines that were investigated. The release of cytochrome c 
from the mitochondria activates caspase-9, which subsequently cleaves and 
activates the effector caspase-3. Treatment with AA-861, MK-886, or 
montelukast resulted in caspase-9 and -3 cleavage, and a co-incubation with 
zVAD-fmk, a pan caspase inhibitor, attenuated the cytotoxic effect. 
Together, these results show that treatment with AA-861, MK-886, or 
montelukast induces apoptosis of neuroblastoma cells through the intrinsic 
apoptotic pathway. 
 
This shows that neuroblastoma cells produce LTs that can promote their 
own survival. Other studies suggest that the mechanism underlying the 
increased proliferation and survival induced by LTB4 and LTD4 involves the 
activation of MEK/Erk and PI3K/Akt pathways (Tong et al., 2005; 
Massoumi and Sjolander, 2007) and the upregulation of anti-apoptotic Bcl-2 
(Massoumi and Sjolander, 2007). One research group has shown that BLT2 
activates Nox1/4, followed by the generation of ROS and then activation of 
NF-кβ signaling, which increased cell proliferation, invasion, and metastasis 
(Choi et al., 2010; Kim et al., 2010).  
 
Numerous studies on epithelial cancer cells have revealed cytotoxic and anti-
proliferative effects by treatment with 5-LO pathway inhibitors (Steinhilber et 
al., 2010). Similar to our findings, other studies have shown that 5-LO 
pathway inhibitors primarily induce apoptosis by activation of the intrinsic 
apoptotic pathway (Steinhilber et al., 2010). Remarkably, the treatment of 
neuroblastoma cells with montelukast, a CysLT1 receptor antagonist, was as 
potent as treatment with AA-861 or MK-886 in reducing cell survival and 
inducing apoptosis. Montelukast, which is sold under the trade name 
Singulair, is used in clinics for the treatment of asthma in children and adults. 
In addition to binding to the CysLT1 receptor, montelukast has been 
reported to directly inhibit 5-LO activity (Ramires et al., 2004).  
 
It has been shown that 5-LO inhibitors can induce apoptosis by mechanisms 
independent of 5-LO inhibition (Fischer et al., 2010). To investigate this, we 
added LTs to cells treated with the 5-LO inhibitor AA-861. Addition of LTB4 
and LTD4 alone or in combination with the 5-LO product 5-HETE could 
abrogate the cytotoxic effect of AA-861. We also specifically suppressed 5-
LO protein expression, and the subsequent LT production by siRNA 
transfection, which resulted in a 35% reduced neuroblastoma cell growth. 
The same anti-proliferative effect was observed when CysLT1 expression was 
reduced. These data show that LTs are important for neuroblastoma cell 
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growth, but nevertheless we cannot exclude the possibility that off-target 
effects of the compounds may contribute to the observed cytotoxicity. 
 
One LTB4 receptor antagonist, LY293111, has shown a promising efficacy in 
the treatment of cancer, both in vitro and in vivo. Three phase I studies proved 
that LY293111 in combination with cytostatic drugs was safe and well 
tolerated in patients. However, the results from two phase II studies in 
patients with non-small cell lung or pancreatic cancer failed to demonstrate 
any improvement in a progression-free survival (Adrian et al., 2008). 
 
 
4.3 TARGETING PROSTAGLANDIN SIGNALING IN VIVO 
(PAPER IV) 
A lot of research has focused on the role of inflammation and inflammatory 
cells and mediators in adult cancers, while much less is known about the 
importance of inflammation in childhood cancer and in neuroblastoma 
(Seeger, 2011). To investigate the composition of immune cells in 
neuroblastoma and the effect of COX-inhibition, we used the TH-MYCN 
mouse model that spontaneously develops neuroblastoma-like tumors 
originating from the neural crest (Weiss et al., 1997; Hansford et al., 2004). In 
our hands, 100% of the homozygous mice developed palpable tumors at four 
to seven weeks of age, and 50% of the hemizygous mice developed tumors 
between six and 19 weeks (Rasmuson et al., unpublished). To be able to 
analyze small, unpalpable tumor lesions, we used homozygous mice that were 
four and a half to six weeks old. At the age of five weeks, we could detect 
small poorly vascularized tumor lesions in all dissected homozygous animals. 
One week later, when the mice were six weeks old, the tumors had grown 
much larger and comprised a significant portion of the abdominal cavity, 
often growing onto and displacing the kidneys. 
 
 
4.3.1 Characterization of the TH-MYCN tumor 
microenvironment during tumor progression 
4.3.1.1 T cells 
To investigate whether T cells were present in TH-MYCN tumors, the 
tumors were stained with the T cell marker CD3. The staining revealed that 
tumor-infiltrating CD3+ T cells were present in the tumors as well as in blood 
vessels. FACS analyses of whole tumor single-cell suspensions showed that in 
small tumor lesions, 0-0.2 g, 63% of the total number of CD45+ 
hematopoietic cells consisted of T cells. In larger tumors, 0.5-2.2 g, the 
proportion of T cells was significantly smaller, and comprised only 27% of 
the CD45+ cells. T cells can be subdivided into T-helper cells, expressing the 
CD4 co-receptor, and CTLs, expressing the CD8 co-receptor. We further 
   47 
characterized the T cells by anti-CD4 and CD8 staining. FACS analysis 
showed that both T-helper cells and CTLs are present in TH-MYCN tumors, 
with a higher number of T-helper cells. Calculating the CD4/CD8 ratio in 
relation to the tumor weight revealed a significant increase in T-helper cells 
during the tumor progression. Moreover, we investigated the presence of 
Treg, an immune suppressive subpopulation of T-helper cells that expresses 
the transcription factor FOXP3. Treg constituted 8-20% of the T-helper cell 
population, and this proportion was consistent throughout the tumor 
progression. 
  
Tumor infiltration of CD4+ T cells correlates with a good prognosis for colon 
and lung cancer patients, whereas the opposite has been documented for 
breast and renal cancer patients (DeNardo et al., 2010). One important factor 
contributing to these paradoxical findings is that the CD4+ T-cell population 
can be subdivided into several functionally different subtypes, including Th1, 
Th2, and Treg. Activation of Th1 type responses activates anti-tumor 
programs, while the activation of Th2 and Treg responses promotes tumor 
progression by stimulating immune suppression, angiogenesis, and tissue 
remodeling. The Th1 and Th2 cells exert their effect by the release of 
different cytokines. Th1 cells express interferon γ (IFNγ), tumor necrosis 
factor α (TNFα), IL-2, and IL-12, whereas the Th2 cells typically secrete IL4, 
IL5, IL-6, IL-10, and IL-13 (DeNardo et al., 2010). 
 
Th1 cells can initiate an effective anti-tumor response by activating CTLs, 
one of the cell types that can directly kill tumor cells, and by releasing high 
levels of IFNγ, TNFα and cytotoxic granules, all of which are directly toxic to 
cancer cells (DeNardo et al., 2010). We could detect CTLs in TH-MYCN 
tumors, although with a gradual decrease during tumor growth. To elucidate 
whether the tumor-associated T cells had the capacity to mount an effective 
Th1 effector response, we stimulated the cells ex vivo with PMA and 
ionomycin for five hours, and analyzed the intracellular concentration of 
IFNγ by flow cytometry. The analysis revealed that both CD4+ and CD8+ 
cells could produce IFNγ, thus indicating that these cells have the capacity to 
initiate a Th1 response. The ability of CTLs to kill tumor cells is also 
dependent on the expression of major histocompatibility complex (MHC) 
class 1 on tumor cells. Many tumor cells have lost or downregulated their 
expression of MHC class 1, and thus cannot be recognized and killed by the 
CTLs. Therefore, we evaluated the expression of MHC class I on TH-
MYCN tumor cells. We detected a low expression of the H-2Db allele, but no 
expression of the H-2Kb allele. 
 
4.3.1.2 Myeloid cells 
We also stained whole tumor single-cell suspensions with F4/80 in 
combination with CD45 for the detection of macrophages. FACS analysis 
revealed TAMs in all tumors of all stages. In smaller tumors, TAMs 
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constituted less than 10% of the CD45+ cells, while larger tumors had a 
significantly higher proportion at 25%. Macrophages can exert both tumor-
promoting and anti-tumor activities depending on their phenotype. 
Generally, in established tumors, TAMs have an M2-like phenotype and 
promotes tumor growth and progression, which is the opposite effect of the 
M1 phenotype (Mantovani et al., 2008). To characterize the phenotype of 
TAMs that infiltrate TH-MYCN tumors, we evaluated the expression of 
MHC class II and the macrophage mannose receptor (MMR). In small 
tumors, TAMs displayed a high expression of MHC class II and a low 
expression of MMR, thus indicating an M1 polarization, while the opposite 
expression pattern was found for TAMs in larger tumors. Larger tumors 
expressed significantly lower levels of MHC class II and showed a tendency 
towards a higher expression of MMR, both of which indicate an M2 
polarization. 
 
Furthermore, we investigated the presence of dendritic cells, defined as 
CD45+CD11c+, in TH-MYCN tumors. Similar to the TAM, the dendritic 
cells accumulated during the tumor progression. In small tumors, only 6% of 
the CD45+ cells were constituted of dendritic cells, whereas larger tumors had 
a median of 22%. The dendritic cells present in large tumors displayed a 
reduced expression of MHC class II, indicating an immature phenotype 
(Fainaru et al., 2010). Dendritic cells within tumors often display an immature 
phenotype, with a subsequent impaired ability to initiate adaptive anti-tumor 
immune responses (Gabrilovich, 2004). Immature dendritic cells also directly 
promote tumor growth by stimulating angiogenesis (Fainaru et al., 2010). 
Studies have shown that TAMs, MDSCs and various other tumor-derived 
factors can restrict the maturation and function of the dendritic cells within 
tumors (Gabrilovich, 2004).  
 
Similar to the TAMs and dendritic cells, we detected an accumulation of 
MDSCs in tumors during progression. MDSCs are a diverse group of 
immature myeloid cells with immunosuppressive functions that are 
characterized by the expression of GR1 and CD11b in mice (Ostrand-
Rosenberg and Sinha, 2009). The immunosuppressive actions of MDSCs 
include the suppression of T cell activation, the induction of Treg, and the 
production of cytokines, which helps skew the tumor microenvironment 
towards a tumor-promoting Th2 type (Ostrand-Rosenberg and Sinha, 2009). 
The MDSCs are activated by pro-inflammatory mediators such as PGE2, IL-
1β, and IL-6 (Ostrand-Rosenberg and Sinha, 2009). 
  
4.3.1.3 Cytokines 
By quantitative real-time RT-PCR we characterized the expression level of 
the cytokines IL-10, IL-6, IL-2, tumor growth factor β (TGF-β) and IFNγ 
relative to the control gene HPRT in TH-MYCN tumors of various sizes. 
The highest expression was detected for the Th2 cytokines IL-10 and TGF-β, 
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while the expression of IL-6 and the Th1 cytokines IL-2 and IFNγ were close 
to or under the detection limit. We did not detect any correlation between the 
level of expression and tumor weight. A significant difference, however, was 
detected when comparing the expression level of IL-10 and TGF-β in tumors 
of homozygous versus hemizygous mice, which could reflect a slower disease 
progression with a subsequently prolonged time to develop a state of chronic 
inflammation. Surprisingly, we detected very low levels of the Th2 cytokine 
IL-6. One possible explanation for this is that the overexpression of MYCN 
downregulates the expression of IL-6 (Hatzi et al., 2002). 
 
Together these results show the presence of an early tumor-associated 
inflammation in tumors from five-week-old mice. These tumors shift toward 
a more immunosuppressive microenvironment with an accumulation of M2 
TAM, immature dendritic cells, and MDSC at the expense of T cells and 
CTLs. 
 
  
4.3.2 Expression of COX and therapeutic treatment with  
a low-dose ASA 
As previously mentioned, our group has shown that human neuroblastoma 
cells overexpress COX-2 and produce PGE2 (paper I), and that treatments 
with COX inhibitors reduce the growth of neuroblastoma xenografts 
(Johnsen et al., 2004). To investigate the effect of COX inhibition on tumor-
associated inflammation, we first evaluated the expression of COX-1 and 
COX-2 in TH-MYCN tumors, and we detected the expression of both 
enzymes by use of immunohistochemistry. FACS analysis confirmed the 
expression of COX-1 and COX-2 and revealed that 63% of the 
neuroblastoma cells expressed COX-1, whereas only 31% of cells expressed 
COX-2. A similar pattern was observed for CD45+ hematopoietic cells, in 
which 95% expressed COX-1, though only 11% expressed COX-2. Because 
of the high expression of COX-1 in the tumor cells, we decided to treat 
animals with a low-dose ASA. Eight homozygous mice were treated with 10 
mg/kg of ASA, which corresponds to 60 mg for an adult human, calculated 
according to body surface area (Reagan-Shaw et al., 2008). The treatment was 
given by oral gavage, and treatment started when the animals reached 4.5 
weeks of age and continued for 10 consecutive days. Strikingly, the low-dose 
ASA treatment significantly reduced tumor growth, as the median tumor 
weight for treated animals was 0.25 g compared to 1.15 g for the control 
tumors. FACS analysis of whole tumor single-cell suspensions showed that 
ASA-treated tumors had a composition of inflammatory cells that resembled 
those found in small tumors. Because all ASA-treated tumors had a small 
tumor weight, it is difficult to conclude whether the altered pattern of 
inflammatory cells is due to the treatment or to the bystander effect of 
reduced tumor growth. 
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In general, a high dose of ASA (1 g) is anti-inflammatory by its inhibition of 
the COX enzymes, whereas a low dose (75-150 mg) is cardioprotective 
through the inhibition of platelet-derived TXA2. However, a recent study 
documented that even low doses of ASA could act in an anti-inflammatory 
manner on acute inflammatory responses in humans (Morris et al., 2009). 
 
During the time of this study, several articles have been published that 
describe a prominent effect with low doses of ASA (75-300 mg) in cancer 
prevention (Rothwell et al., 2010; Salinas et al., 2010; Rothwell et al., 2011). 
Additionally, one randomized control trial showed that 600 mg of ASA per 
day significantly reduced the risk of developing cancer in patients with Lynch 
syndrome, a hereditary form of colorectal cancer (Burn et al., 2011). The 
underlying mechanism behind this observed effect is not yet clear, although 
many speculations have been reviewed by Langley et al (Langley et al., 2011). 
These include COX-specific effects with an inhibition of COX-1 in platelets 
with a subsequent inhibition of TXA2 biosynthesis, the inhibition of COX-2 
and tissue PGs, and COX-independent effects such as the inhibition of NF-
кβ, Wnt, and TGF-β signaling. Another proposed mechanism by which ASA 
may inhibit tumor growth is the production of ATLs (Greene et al., 2011). In 
this study, we have shown that even a therapeutic treatment with a low dose 
of ASA results in a significantly reduced neuroblastoma tumor growth in the 
aggressive TH-MYCN model. 
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5 SUMMARY AND CONCLUSIONS 
In this thesis, the importance of PGE2 and LTs in cancer has been 
investigated. COX-1, COX-2, and mPGES-1 are key enzymes in the 
metabolism of arachidonic acid to PGE2, whereas the 5-LO pathway 
catalyzes the production of LTs. We have investigated the expression of key 
proteins in these two pathways and their role in tumor cell growth and 
survival. The result may be summarized as follows: 
 
 
• Neuroblastoma cells express the four PGE2 receptors EP1-EP4. 
 
• PGE2 acts as an autocrine and/or paracrine proliferation and survival 
factor for neuroblastoma. 
 
• mPGES-1 is differentially expressed in prostate cancer. 
 
• Downregulation of mPGES-1 reduces the clonogenic capacity and 
delays tumor growth of prostate and lung cancer xenografts. 
 
• Enzymes and receptors of the 5-LO pathway are expressed in 
neuroblastoma.  
 
• LTs act as autocrine/paracrine proliferation and survival factors in 
neuroblastoma. 
 
• Inhibition of enzymes within the 5-LO pathway or blocking the LT 
receptors leads to neuroblastoma cell death by induction of apoptosis.  
 
• A progressive inflammatory tumor microenvironment is present in 
tumors from the transgenic TH-MYCN neuroblastoma model.  
 
• COX-1 and COX-2 are expressed in TH-MYCN tumors.  
 
• Therapeutic treatment with a low-dose ASA reduces neuroblastoma 
TH-MYCN tumor growth.  
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6 FUTURE PERSPECTIVES  
A compelling piece of evidence demonstrates that COX-2 is involved in 
tumor growth and progression in multiple cancers, but the exact mechanism 
behind its tumor-promoting effects is still not fully clear. Metabolism through 
COX-2 involves several different substrates and downstream synthases, with 
the subsequent formation of a whole group of bioactive compounds that 
signals through multiple receptors. In general, a given cell type forms only 
one or two of these products in abundance. We and others have shown that 
PGE2 signaling in cancer cells is complex and involves several EP receptors. 
In addition, stromal cells within the tumor may also express one or several of 
these receptors (Reader et al., 2011). Accordingly, targeting only one EP 
receptor to inhibit tumor progression and improve patient outcome may 
prove insufficient. Inhibition of mPGES-1 may represent a more promising 
target for cancer therapy, because this stops most, if not all, PGE2 production 
and subsequently all PGE2 signaling. Future studies will reveal if PGE2 
accounts for all the tumor-promoting properties of COX-2, and if mPGES-1 
inhibitors and COX-2 inhibitors have a similar potential in reducing tumor 
growth and metastatic spread. 
 
Inhibition of COX-2 in cells expressing both the COX-2 and 5-LO pathways 
could, theoretically, result in a metabolic shunt of free arachidonic acid over 
to the 5-LO pathway, with a subsequent increased production of pro-
inflammatory LTs. This has indeed been reported in a study in which non-
smokers and smokers were given celecoxib for one week, which resulted in 
lower urinary levels of PGE2 but significantly increased urinary LTE4 
(Duffield-Lillico et al., 2009). Since neuroblastoma cells express both the 
COX-2 and 5-LO pathways, and both PGE2 and LTs promote cell survival 
and growth, the best therapeutic treatment strategy would be to inhibit both 
pathways through combination therapy.  
 
The high expression of COX-1 in TH-MYCN tumors also raises the question 
of the importance of COX-1 in human neuroblastoma. To date, no studies 
have investigated this. Furthermore, one previous study reported that the 
TH-MYCN tumors were non-immunogenic and lacked infiltrating immune 
cells (Moore et al., 2008). In contrast, our data clearly demonstrates a 
progressive inflammatory tumor microenvironment in TH-MYCN tumors, 
making this a useful model for studying the role of cancer-related 
inflammation in neuroblastoma in vivo. 
 
Whether a low-dose ASA should be included in the treatment for 
neuroblastoma remains to be further investigated, and the exact mechanism 
behind its anti-tumoral effect remains to be further clarified. Before 
incorporating a low-dose ASA in the treatment protocol, the most effective 
dosing and time scheduling must also be established. Today ASA is not 
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recommended for children under the age of 16 years due to an increased risk 
of developing Reyes syndrome when using ASA for viral illnesses. Therefore, 
a careful evaluation of the potential pros and cons is essential. 
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7 POPULÄRVETENSKAPLIG SAMMANFATTING  
I Sverige drabbas varje år över 50.000 vuxna och cirka 300 barn av cancer. 
Trots stora framsteg så är cancer den näst vanligaste dödsorsaken för både 
barn och vuxna i Sverige. Behovet av att hitta nya behandlingar som kan 
förbättra överlevnaden och minska de sena komplikationerna är stort. 
Genom en ökad biologisk förståelse kan man utveckla mer målstyrda 
behandlingar som förhoppningsvis kan förbättra behandlingsresultaten.    
 
Neuroblastom är en cancersjukdom som drabbar små barn, de flesta 
insjuknar redan innan två års ålder. Neuroblastom uppkommer i omogna 
celler av det sympatiska nervsystemet, som är en del av det icke-viljestyrda 
nervsystemet som har till uppgift att anpassa kroppen till fara och stress. Det 
sympatiska nervsystemet stäcker sig längs med båda sidorna av ryggraden och 
förgrenar sig i bålen till bl.a. binjuren. Neuroblastom kan utvecklas var som 
helst längs det sympatiska nervsystemet men uppkommer oftast i binjuren. 
Neuroblastom är en av de vanligaste cancerformerna hos barn men det är 
också den barncancer som har sämst prognos. Trots en intensiv behandling 
med kirurgi, cytostatika och strålning så är överlevnaden för barn i 
högriskgruppen endast 55% och den totala överlevnaden för alla barn med 
neuroblastom är 74%.   
 
Inflammatoriska celler och signalsubstanser är en viktig del av tumörmiljön 
där de bidrar till en ökad tumörtillväxt. Antiinflammatoriska behandlingar har 
visat sig kunna minska canceruppkomst och tumörtillväxten. 
Neuroblastomceller har en förändrad fettsyrabalans jämfört med normala 
nervceller. De har en ökad nivå av den inflammatoriska omega-6 fettsyran 
arakidonsyra men en lägre nivå av antiinflammatoriska omega-3 fettsyror. 
Arakidonsyra som finns lagrat i cellens membraner omvandlas via tre 
enzymvägar, cyklooxygenaser (COX), lipoxygenaser (LO) och cytokrom p450 
till olika signalsubstanser, eikosanoider. Vi har i en tidigare studie visat höga 
nivåer av COX-2 i neuroblastom, som omvandlar arakidonsyra till 
inflammatoriska prostaglandiner. Vi har också visat att om man behandlar 
neuroblastom med COX hämmare så minskar tumörtillväxten. I min 
avhandling har jag undersökt betydelsen av eikosanoider i cancer, med fokus 
på neuroblastom.   
 
För att utreda varför COX-2 är viktigt i neuroblastom undersökte vi 
betydelsen av dess produkt prostaglandin E2 (PGE2). Våra resultat visar att 
alla fyra PGE2 receptorer finns i neuroblastom. Neuroblastomceller kan 
också själva producera PGE2 som stimulerar cellöverlevnad och celldelning. 
Om signaleringen via PGE2 receptorerna förhindras, hämmas celltillväxten. 
Resultaten pekar på att flera av receptorerna är viktiga för 
neuroblastomcellernas överlevnad. Vi undersökte också effekten av att 
specifikt blockera bildandet av PGE2 genom att hämma det enzym som ligger 
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nedströms om COX-2 som specifikt ansvarar för omvandlingen till PGE2, 
mikrosomalt PGE syntas 1 (mPGES-1). Resultaten visar att om man tar bort 
mPGES-1 så reduceras prostatacancercellers och lungcancercellers förmåga 
att klona sig och tumöruppkomsten hindras.  
 
En annan väg för arakidonsyra är via 5-Lipoxygenas (5-LO) och en 
produktion av inflammatoriska leukotriener. Denna avhandling visar att alla 
enzymer i 5-LO kaskaden samt leukotrienreceptorerna finns i neuroblastom. 
Neuroblastomceller kan också producera leukotriener vilka verkar som 
cellens egentillverkade tillväxtfaktorer. Blockerar man produktionen av 
leukotriener eller leukotriensignaleringen, induceras en programmerad celldöd 
hos neuroblastomceller.  
 
I barncancer är den inflammatoriska komponenten av tumörmikromiljön inte 
så väl studerad. Vi visar här på en tidig närvaro av inflammatoriska celler, i 
tumörer från en transgen musmodell som spontant utvecklar neuroblastom. 
Vi visar också att kompositionen och fenotypen av dessa celler förändras när 
tumören växer. Sammansättningen och fenotypen av de inflammatoriska 
celler som finns i små tumörer är mer gynnsam än i stora tumörer. De stora 
tumörerna domineras av celler som bidrar till tumörtillväxt och förhindrar ett 
aktivt angrepp mot tumörcellerna. Behandlar man dessa djur med en låg dos 
av anti-inflammatorisk acetylsalicylsyra (aspirin) bibehålls den gynnsamma 
kompositionen av inflammatoriska celler och tumörerna växer långsammare.   
 
Sammanfattningsvis visar studierna i den här avhandlingen att både PGE2 
och leukotriener verkar som neuroblastomcellers egentillverkade 
tillväxtfaktorer. Resultaten visar på att en specifik blockering av PGE2 och 
leukotriensignaleringen skulle kunna utgöra nya behandlingsmål får barn 
drabbade av neuroblastom.      
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